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ABSTRACT 
This dissertation describes two very different projects. The first project focuses on 
the binding of a silent agonist to a ligand gated ion channel. The second project focuses on 
the study of development of new longer wavelength photolabile protecting groups for use 
in a biological setting to enable the spatially and temporally controlled release of 
biologically active small molecules.  
Chapter I introduces ligand gated ion channels and in particular a model of agonist 
binding at the nicotinic acetylcholine receptor. In addition, the nonsense suppression 
methodology used to incorporate the non-canonical amino acids required to probe non-
covalent binding interactions is detailed. The second chapter details the use of non-
canonical amino acids to study the binding of silent agonist NS6740 at the nicotinic 
acetylcholine receptor a7 subunit and the discovery of a novel hydrogen bond that 
modulates silent agonist activity. 
Chapters III, IV and V focus on efforts to expand the scope of photolabile protecting 
groups towards designing longer wavelength derivatives. Chapter III introduces the topic 
of photoremovable protecting groups and details the mechanist background of a quinone 
methide based photochemical protecting group.  
The fourth chapter investigates the use of quinoline and quinolinium derivatives as 
photochemical quinone methide precursors. Two quinoline derivatives were found to form 
a quinone methide transient when irradiated. Quinolinium derivatives proved photostable, 
most likely due to the electron withdrawing nature of the quinolinium.   
The final chapter details efforts to improve the photochemical reaction efficiency 
of quinone photoreduction by using a radical decarboxylation strategy to trap the charge 
transfer state. Synthesis of two glycine containing quinone compounds is detailed and their 
photochemistry is evaluated. Both proved to be photostable. 
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Chapter 1 
 
INTRODUCTION: NICOTINIC ACETYLCHOLINE RECEPTOR 
 
1.1   Motivation 
The brain is composed of a complex network of neurons that communicate via the 
propagation of electrical impulses or action potentials. An action potential travels the 
length of the neuron until it reaches a synapse junction where it must be converted into a 
chemical signal to cross the synaptic cleft (Figure 1.1). Neurotransmitters are the small 
molecule chemical signals that diffuse across the synaptic cleft and bind integral 
transmembrane receptors on the post synaptic cell. These receptors then undergo a 
conformational change that allows ions to flow across the membrane and initiate a new 
electrical signal. This process of electrical to chemical and back to electrical underlies all 
brain activity including sensory processing, movement, and memory. Disruptions to this 
process are responsible for many neurological disorders and diseases. It is therefore 
important to understand these processes at a chemical level. This first part of this thesis 
looks at a specific receptor, the nicotinic acetylcholine receptor (nAChR), binding to a new 
class of drugs.   
 
1.2   Nicotinic Acetylcholine Receptors: A Ligand Gated Ion Channel 
Nicotinic acetylcholine receptors (nAChRs) are part of the Cys loop superfamily of 
pentameric ligand gated ion channels (pLGICs). Upon neurotransmitter binding pLGICs 
undergo a conformational change allowing ions to flow through a channel across the 
membrane. This flow of ions can either initiate an excitatory response, generating an action 
potential such as in the cation permeable Cys-loop LGICs - nAChRs and type 3 serotonin 
(5-HT3A) receptors or can be inhibitory, terminating an electrical signal such as in the anion 
permeable receptors - type A g-aminobutyric acid (GABAARs), and glycine receptors 
(GlyRs).1 As the name implies nAChRs bind both the native neurotransmitter acetylcholine 
and nicotine, the addictive component of cigarettes. nAChRs are a major pharmaceutical 
	 2 
target in many neurological disorders, including addiction,2,3 Alzheimer’s disease,4 and 
schizophrenia.5 
 
Figure 1.1: Neuronal communication via synaptic transmission: A) Cartoon of two nerve cells. Red box 
shows the synapse between the two cells. B) At the synapse neurotransmitters are released from the 
presynaptic nerve in response to an electrical signal and diffuses across the synaptic cleft to bind receptors 
on the postsynaptic nerve cell. C) Ligand gated ion channels (LGICs) undergo a conformational change when 
a neurotransmitter binds, opening a pore and allowing ions to cross the plasma membrane. 
 
All Cys-Loop receptors, including nAChRs, have a common global architecture 
containing five subunits arranged in a circular configuration around a central pore (Figure 
1.2).6 The five subunits and can be either homomeric or heteromeric. Each subunit contains 
a large extracellular N-terminal domain composed mainly of b-sheets, a membrane 
spanning domain composed of four a-helices (M1-M4), and a variable intracellular domain 
composed mainly of the M3-M4 loop important for transport and regulation.7 The binding 
site is at a conserved location in the extracellular domain at the interface of two subunits.  
There are 17 nAChR subunits a1-a10 (a8 is only found in avian species) b1-b4, g, 
d, and e.8,9 The neuronal nAChR subunits, a2-a7, a9, a10 and b2-b4, combine in varying 
combinations and stoichiometries to form functional receptor subtypes, each with its own 
unique pharmacology, function, and localization. (The “muscle type” a12b1gd/e is only 
found in the peripheral nervous system and at neuromuscular junctions.) The two most 
common neuronal subtypes found throughout the brain are a4b2 and a7. This thesis will 
	 3 
focus on a7, which is a drug target for its role in neurological disorders including 
schizophrenia10,11 and Alzheimer’s,4,12,13 as well as for its role in the cholinergic anti-
inflammatory pathway.14,15 
 
Figure 1.2: The nicotinic acetylcholine receptor (nAChR). A) Diagram of common subunit structure to all 
Cys-loop receptors including the nAChR: extracellular domain contains a Cys-loop formed by disulfide bond 
and the orthosteric ligand binding site, four a-helixes from the transmembrane domain and an intracellular 
domain made up mostly of the M3-M4 loop. B) Examples of homomeric and heteromeric arrangements of 
nAChR subunits in a pentameric assembly around a central pore. C) Crystal structure of the human a4b2 
heteromeric nAChR (PDB ID: 5KXI).7 
	
1.3 Cation-p Binding Box 
In a7, as with all other nAChRs, the orthosteric agonist binding site is located at 
the interface of two subunits, in the extracellular domain. Each binding site is composed of 
six loops, three from the primary face (loops A, B and C), and three from the 
complementary face (loops D, E and F).16–18 A group of five highly conserved aromatic 
residues at the binding site form an “aromatic box” around the ligand — a tyrosine on loop 
A (TyrA Y115), a tryptophan on loop B (TrpB, W171) and loop D (TrpD, W77), and two 
tyrosine residues on loop C (TyrC1 and TyrC2, Y210 and Y217) (Figure 1.3).19 Despite 
the perfect conservation of these aromatic residues within the nAChR family, subtype 
	 4 
specific variations in agonist binding patterns have been noted.19,20 In a7 three noncovalent 
interactions have been identified as functionally relevant for agonist binding.  
The first important interaction for agonist binding is a cation-p. The cation-p is a 
strong noncovalent electrostatic interaction between a cation and the quadrupole induced 
negative electrostatic potential surface on the face of an aromatic residue.21,22 Typical 
nAChR agonists contain a cationic amine, either a protonatable amine or a quaternary 
ammonium, that forms a noncovalent cation-p interaction with a conserved aromatic 
residue of the aromatic box. Unique among nAChRs, a7 makes a cation-p between TyrA 
and the ligand.23 In all other nAChRs studied to date the primary aromatic residue involved 
in the cation-p is the tryptophan on loop B.20,23–28 For the potent a7 agonist, epibatidine, a 
second stronger cation-p interaction with TyrC2 was also identified.23 Work by Mike Post 
in the group has shown that secondary amines, such as metanicotine and varenicline, form 
a duel cation-π with TyrC2 and TrpB at a4b2.29 Epibatidine is not a secondary amine and 
remains the only drug to exhibit duel functional cation-p activity at a7.  
 
Figure 1.3: Orthosteric binding site for the a7 nAChR. Five aromatic residues comprise the aromatic binding 
box. These residues are labeled as such: TyrA (Y115), TrpB (W171), TyrC1 (Y210), and TyrC2 (Y217) 
come from the principal face (green) of one subunit and the final residue of the aromatic box TrpD (W77) 
lies on the complementary face (purple).  Image based on an a7 - acetylcholine binding protein (AChBP) 
chimera bound to epibatidine (not shown) (PDB ID: 3SQ6).17 
	 5 
Our group has also identified two hydrogen bonds that are functionally important 
for agonist binding in nAChRs. The NH group of non-quaternary amines, such as nicotine, 
hydrogen bonds with the backbone carbonyl of TrpB.25,27,30 In a7, this interaction was 
observed for epibatidine, a potent agonist, and varenicline, but not for quaternary amine 
agonist ACh as expected.23,31 (Nicotine is a very weak agonist of a7, which prevented its 
study.) The other hydrogen bond occurs between the distal, from the cationic amine, end 
of the agonist and the backbone NH of residue Leu119 on the complementary face.31–33 
This interaction is very important in other nAChRs such as muscle type and a4b2,33 but in 
a7 only the super agonist epibatidine has shown a greater than two-fold effect for mutation 
of this hydrogen bond.31 Together these three interactions are the bases of nAChR agonist 
binding and are the bases of the a7 pharmacophore.   
Historically there was limited structural information about nAChRs. Initially low 
resolution cyro-em34 structures provided information about overall globular structure, and 
the crystal structures of a soluble Acetylcholine binding protein (AChBP)17,18,35 provided 
information on the bind site in the extracellular domain.  Subsequent prokaryotic homology 
models provided insights into changes between the open and closed states.36–39 Recently in 
2016 a high-resolution structure of nACHR a4b2 was published.7,40 Despite improved 
structural information, crystal structures don’t capture protein dynamics nor are there 
crystal structures of every subtype. Structure function studies provide an alternative way 
to implicate functionally relevant interactions of ligand binding, conformational 
rearrangement and receptor activation.   
 
1.4   Structure Function Studies 
Sight directed mutagenesis has been extensively been used by biochemists to probe 
for the specific chemical interactions that are responsible for protein function. However, 
this methodology is limited in scope because the 20 naturally occurring amino acids do not 
provide the subtlety in perturbation required to identify the distinct non-covalent 
interactions, such as cation-p and hydrogen bonding, that are important for protein function 
and our lab is interested in isolating. Subtler mutations are needed to map the important 
interactions responsible for ligand recognition and for the development of a pharmacophore 
model. The Dougherty lab has developed a protocol for the in vivo incorporation of non-
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canonical amino acids;41–43 this has proved a powerful tool for studying structure-function 
relationships in ion channels. This provides a way to study specific interactions of a protein 
at a chemical scale.  
Nonsense suppression allows for the in vivo site specific incorporation of non-
canonical amino acids.19,44 This is accomplished by interruption of normal ribosomal 
function by inserting a stop codon or frameshift mutation, “a nonsense mutation,” in the 
gene of interest (Figure 1.4). Normally a stop codon (UAG, UGA and UAA) results in 
termination of protein synthesis. However, in the presence of an engineered “suppressor 
tRNA” that recognizes the nonsense mutation – via the appropriate anti codon – and 
charged with the desired non-canonical amino acid, site specific incorporation of a 
noncanonical amino acid into the nascent protein is possible. This suppressor tRNA must 
be orthogonal to the host system to prevent re-charging via endogenous aminocyl tRNA 
synthetase. Essentially nonsense suppression allows for the “Hijacking” of the ribosome 
and other machinery of the cell to synthesize, fold, and post translationally modify a protein 
with site specific incorporation of a noncanonical amino acid.  
 
Figure 1.4: Schematic of nonsense suppression during translation. Orthogonal tRNA with correct anti-codon 
recognizes the stop/nonsense mRNA codon at site of interest and the ribosome incorporates the non-canonical 
amino acid into the nascent protein chain.  
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For nonsense suppression, a non-canonical amino acid must be attached to the 
suppressor tRNA, and in our lab this is achieved chemically. To ensure correct attachment 
and minimize degradation this is done in two steps.43 First, the non-canonical amino acid 
is reacted with dCA, a dinucleotide that mimics the final uniform two bases of tRNA, and 
second this structure is enzymatically ligated to an orthogonal 74-mer suppressor tRNA. 
The advantage of this methodology is a tRNA synthetase is not required, and therefore 
incorporation of new non-canonical amino acids is facile and a large array of side chains 
with very subtle perturbations differing in as little as a single atom can be incorporated. 
The disadvantage of this method is the yield of protein depends stoichiometrically on the 
quantity of charged tRNA added to the system. Because of reagent limitation and inherent 
inefficiencies in the system only attomoles of protein are generated.19 Most spectroscopic 
techniques require much larger quantities of protein thus we use an equally sensitive 
technique for studying ion channels– electrophysiology. 
 
1.5   Electrophysiology  
Neuroscientists routinely use electrophysiology techniques to study ion channels 
by observing changes in electrical currents and potentials across lipid membranes. 
Electrophysiology has been used at multiple scales from individual proteins all the way up 
to mapping neural networks and can be used to interrogate endogenous activity in living 
animals and ion channels expressed in heterologous systems such as the oocytes from 
Xenopus laevis, which our lab employs. 
Oocytes from X. laevis (the African clawed frog) are a classic model system for 
studying ion channel function because of their large size (1 mm in diameter), minimal 
expression of endogenous ion channels and ability to express eukaryotic proteins. Oocytes 
are large enough for direct injection of mRNA or cDNA and have the requisite cellular 
machinery for protein synthesis, assembly and surface trafficking of ion channels.45–47 
Expressed ion channels have almost identical physiology to receptors expressed in other 
cell systems or those found in native neuronal environments. They are also amenable to 
nonsense suppression as acylated tRNA can also be directly injected into the cell alongside 
mRNA containing the correct nonsense mutation in the gene of interest (Figure 1.5).19  
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Figure 1.5: Nonsense suppression methodology for non-canonical amino acid incorporation into ion 
channels in Xenopus laevis oocytes. A) mRNA with a stop codon, “nonsense mutation,” at site of interest. B) 
orthogonal tRNA with correct anticodon chemically acylated to a non-canonical amino acid of interest. C) 
Injection of both mRNA and tRNA into the oocyte. D) Oocyte machinery translates, post translationally 
modifies and traffics to the surface the ion channel of interest with the non-canonical amino acid incorporated 
at the desired position. E) Two electrode voltage clamped (TEVC) electrophysiology readout of ion channel 
function. F) Application of increasing concentrations of agonist result in more channels opening and an 
increase of observed current during TECV experiments. G) After normalization, responses are plotted and fit 
to the Hill Equation. The concentration that results in a half maximal response, EC50, provides a functional 
comparison between mutations. A gain of function results in a leftward shift and decreases the EC50 while a 
loss of function results in a rightward shift and an increase on the EC50. 
Agonist binding to a LGIC results in the channel opening and ions flowing through 
the pore to generate a current. This current can be measured easily using a whole cell two-
electrode voltage clamp (TEVC) setup (Figure 1.5). In TEVC, the oocyte is impaled with 
two glass electrodes. The first electrode measures the internal potential relative to an 
external reference electrode in the oocyte bath media and the second electrode responds to 
variations in voltage by applying an appropriate current to maintain a constant “clamped” 
membrane potential. The variation in current required to maintain a clamped membrane 
potential provides a measure for the net charge flowing through ion channels in the open 
state. This system is very sensitive, enabling currents of tens of nA to µA to be measured 
during whole cell recording and requires only a very small amount of protein for 
measurable signal response. This means that nonsense suppression can be used to study 
ion channels. An eight-channel recoding rig — the OpusXpress 6000A — in our lab makes 
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TEVC experiments much more efficient because it is capable of simultaneous multi-
channel voltage clamping, buffer perfusion, and drug application. 
The major electrophysiology functional assay used in this dissertation is the dose 
response. In a typical does response experiment an oocyte expressing the LGIC of interest 
is subjected to increasing doses of agonist and the resulting whole-cell currents are 
measured. After normalization to max observed current and plotting, the data are fit to the 
Hill equation, a simplified model of cooperative binding: ! " = $%&'()( [,]./01)34	 	 	 	 		(Eq. 1. 1) 
where I is the observed whole cell current, [A] is the agonist concentration, Imax is the 
current at saturating concentrations of agonist, EC50 is the concertation of agonist required 
to elicit a half maximal response and hH is the Hill coefficient. EC50 provides a readout for 
the magnitude of the energetic perturbation caused by a given mutation; The log(fold-
change in EC50) is roughly proportional to the ∆∆G value. An increase in EC50 corresponds 
to a loss of function (more agonist is required to open the same number of channels) and a 
decrease in EC50 corresponds to a gain in function (less agonist is needed to open the same 
number of channels). 
 
1.6   Positive Allosteric Modulators  
In addition to agonists that bind at the orthosteric binding site, compounds have 
been developed that can modulate a7 function from binding sites distant from the agonist 
binding site, a process known as allosteric modulation. These compounds can either act as 
positive allosteric modulators (PAMs) that in the presence of an agonist can increase 
currents, or as negative allosteric modulators (NAMs) which inhibit agonist activation or 
block the channel suppressing currents. PAMs can potentiate agonist currents in two ways, 
either by reducing the EC50, a “gain of function,” and/or by increasing current response for 
all doses (Figure 1.6). There are two major classes of PAMs, Type I and Type II, which 
are identified by their macroscopic effects on channel conductance. 48 Type I PAMs, such 
as 5-methoxyindole (5-HI) and genistein, increase peak current most likely through 
decreasing the energetic barrier to opening.49,50 Type II PAMs, such as PNU-120596, slow 
desensitization and can reactivate desensitized receptors in addition to increasing peak 
current (Figure 1.6).49,51 PAMs have received attention as therapeutic agents14,52–54 because 
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they allow for the modulation of receptor activity without interrupting endogenous 
activation. In addition, they show higher selectivity because the allosteric binding site is 
less conserved than the orthosteric binding site potentially reducing side effects.55 Finally, 
they have proven useful tools in probing receptor function.  
 
Figure 1.6: Positive Allosteric Modulators (PAMs). A) Possible Effects of a PAM on EC50 curves: A gain 
of function (red), an increase in signal (blue) or most commonly a combination of both (purple) relative to 
agonist alone (black). B) Two classes of PAMs for a7 nAChRs: type I elicit a change in peak height and type 
II affect peak height as well as closure rate and can also reactivate the desensitized state. 
 
1.7   Summary of Part One of Dissertation Work 
In part one of this dissertation non-canonical amino acids were incorporated into 
the a7 nAChR using nonsense suppression, and binding of the silent agonist, NS6740, to 
the receptor was characterized using electrophysiology. Non-canonical mutagenesis of a7 
aromatic box residues revealed a hydrogen bond to the TyrA OH that was detrimental to 
channel opening. Its removal resulted in a gain of function and converted the silent agonist 
NS6740 into a partial agonist. Both type I and II PAMs were used to understand the nature 
of this activity. These results suggest a mechanism by which silent agonist, NS6740, 
functions.  
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Chapter 2 
 
THE BINDING INTERACTIONS OF NS6740, A SILENT AGONIST OF 
a7 THE NICOTINIC ACETYLCHOLINE RECEPTOR	
 
Abstract 
The a7 nicotinic acetylcholine receptor (nAChR) is an important drug target 
for a number of neurological and inflammatory disorders. Silent agonists 
are an emerging class of drugs that bind to the receptor but do not open the 
channel. Instead they shift the receptor to a desensitized state. Silent 
agonists have shown promise at targeting a subset of  a7 nAChR mediated 
signaling processes. We use non-canonical amino acid mutagenesis to 
characterize the binding to a7 by the silent agonist NS6740.  We find that 
like a7 agonists, NS6740 forms a cation-p interaction with TyrA. We also 
showed that NS6740 makes a novel hydrogen bond to TyrA and that this 
interaction is necessary for the silent agonist activity of NS6740. 
 
2.1   Introduction 
The nicotinic acetylcholine receptor (nAChR) a7 subtype1,2 is the second most 
abundant neuronal nAChR subtype, and is found throughout out the brain both 
presynaticaly, where it facilitates neurotransmitter release, and postsynaptically, where it 
modulates synaptic transmission. While a7 subunits predominantly form homomeric 
receptors, heteromeric a7b2 receptors have been reported.3–5 The homomeric a7 nAChR 
is involved in cognitive function and memory has been linked to many neurological 
disorders including Alzheimer’s and schizophrenia.6 a7 is also expressed on non-excitable 
cells including astrocytes, microglia and endothelial cells where it plays a functional role 
in immunity, inflammation and neuroprotection.1,7 The a7 nAChR is currently a drug 
target. 
Despite being one of the most abundant nAChRs in the brain the a7 subtype is not 
optimized for synaptic transmission. Unlike other neuronal nAChRs, it is characterized by 
very short very low probability channel opening.8 This is due to agonist concentration-
dependent desensitization; channel opening occurs when only one or two of the five 
orthosteric binding sites are occupied and binding to additional sites results in 
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desensitization.9–12 Choline, the ubiquitous biological precursor for ACh, is an agonist of 
a7.13 It is also highly permeable to calcium (PCa:PNa of ³ 10).14,15 None of these features 
are ideal for synaptic transmission. Taken together with the fact that a7 is expressed outside 
the synapse of neurons and in non-excitable cells is has been hypothesized that a7 may 
participate in metabotropic signaling as well as ionotropic signaling.16  
Silent agonists are an emerging class of drugs developed to target a7. Upon 
binding, they do not open the channel but rather induce a conformational change which 
stabilizes a desensitized state (Figure 2.1). This can be confirmed by the co-application of 
a type II positive allosteric modulator (PAM) such as PNU-120596, which shifts the 
equilibrium toward a conducting open state, presumably by destabilizing the desensitized 
state and/or stabilizing the open state. It has been proposed that the desensitized and open 
states associated with a silent agonist are different from those associated with a 
conventional agonist.17,18 Silent agonists should not be thought of as competitive 
antagonists. Competitive antagonists simply block agonist binding and do not induce a 
conformational change that is sensitive to binding of a type II PAM.   
 
Figure 2.1: Silent agonist activity. A) Representative current trace for application of acetylcholine (ACh) on 
a7. B) Representative current trace for the silent agonist, NS6740, on a7 and the co-application of NS6740 
and the Type II positive allosteric modulator (PAM) PNU-120596. B) Structure of NS6740 and PNU-120596. 
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The first silent agonist to be characterized, NS6740,19 has been shown in vitro to 
modulate the inflammatory response of microglia cells as part of the cholinergic anti-
inflammatory pathway20 and in mouse models treated neuropathic pain.21 Another silent 
agonist, PMP-072, was shown in mouse models to have anti-arthritic effects.22 The exact 
signaling mechanism behind these physiological effects is unclear, but it has been 
hypothesized that silent agonist may activate a metabotropic signaling pathway in a7.16 If 
true, silent agonists represent novel therapeutic agents for the selective targeting of a 
specific subset of a7-meditated signaling pathways, such as those related to chronic 
inflammation and neuropathic pain.   
Little is known about the core pharmacophore of silent agonists, and a better 
understanding of the binding of silent agonists at the orthosteric site could guide the design 
of new silent agonists. So far all characterized silent agonists have a cationic nitrogen, 
either a protonatable amine or a quaternary ammonium, and are believed to bind at the 
orthosteric site.21 Initial studies on alkylammonium ligands showed that increasing bulk 
around the cation reduced agonist activity while maintaining desensitization activity.17,23 
NS6740 has a bulky bicyclo [3.2.2] ring system, but derivatives of NS6740 lacking the 
bulky bicyclic ring system still exhibit silent agonist activity.24 
Electrophysiology can be used to gain vital structure-function information on ion 
channels. However, silent agonists require a PAM to generate an electrophysiological 
signal, complicating matters. This chapter uses non-canonical amino acid mutagenesis 
(Figure 2.2) to probe the binding of the silent agonist NS6740 at the orthosteric site and 
compares the results to previous work from our lab looking at the binding of typical 
agonists such as acetylcholine (ACh) and nicotine. We find that the silent agonist NS6740 
makes a cation-π interaction to TyrA and a never before characterized, functionally 
significant hydrogen bond to TyrA.  
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Figure 2.2: Structures of the side chains of noncanonical amino acids. A) Tyrosine derivatives. B) 
Tryptophan derivatives. C) Backbone amide to ester mutation strategy for perturbing a hydrogen bond.   
 
2.2 Results  
2.2.1   Measuring binding interactions in the presence of a PAM:   
The metric for measuring the effect of noncanonical amino acid incorporation, 
EC50, is a composite measure of several equilibria, including agonist binding and channel 
gating events. Therefore, there is ambiguity in how a specific mutation shifts EC50, because 
a mutation can affect gating, binding or both. Single channel measurements can provide 
more detailed kinetic analysis on which equilibrium is being perturbed. However, single 
channel studies are labor intensive and are not suitable to this project given the number of 
mutations probed and protein expression limitations for a7.  
Noncanonical amino acid mutagenesis allows for very subtle and precise 
modifications of the protein. This coupled with our knowledge of the structure of the 
binding site, allows us to probe interactions within the binding site, and conclude that 
observed shifts in EC50 are a result of attenuated binding interactions. However, a 
complicating factor in this project is the need to co-apply a PAM with the silent agonist of 
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interest for a signal to be observed. In ion channels, allosteric modulators can induce a 
long-range conformational change to the orthosteric binding site, altering the binding 
affinity of the agonist, or they can modulate the gating transition of the receptor. If the 
former mechanism were operative, it would complicate analysis of silent agonist binding. 
Fortunately, our lab have previously shown that in a7 the type II PAM PNU-120596 does 
not alter the orthosteric binding site, as determined by detailed interactions with the native 
agonist ACh.25 This was done by comparing the impact of a mutation on receptor function 
with or without the co-application of the PAM. Given that PNU-120596 does not alter the 
agonist binding site, we can assume that any change from mutations made to the binding 
site are from an interaction with NS6740 not PNU-120596. As such, studies of NS6740 
were performed in the presence of 10 µM PNU-120596, producing robust signals.  
 Previous work in our lab using PNU-120596 was done by pre-application of the 
PAM to cells before the agonist was applied. This was done to ensure the PAM had come 
to binding equilibrium. At the start of this study the OPUS, our electrophysiology rig, only 
had one working perfusion pump making pre-application impossible without manually 
replacing pipet tips between every does. Only a slight increase to EC50 and minimal 
changes to trace shape were observed when oocytes were not pre-incubated with 10 µM 
PNU-120596 compared to cells that were pre-incubated for 30 seconds (Figure 2.3). 
Preincubation can also serve as a control to ensure mutations do not convert PNU-120596 
from a PAM to an allosteric agonist. This was not a concern since all mutations had 
previously been screened by Marotta et al..25 All subsequent experiments were carried out 
without any pre-incubation. 
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Figure 2.3: Effect of pre-incubation with PAM PNU-120596 on NS6740 response. A) Shows EC50 curves 
with (98 ± 11 nM) and without pre-incubation (62 ± 4.5 nM). B) Shows representative traces with and without 
pre-incubation.  
2.2.2   Binding interaction of TyrA with NS6740: 
First we looked at whether the silent agonist, NS6740, still forms a cation-π 
interaction with TyrA (Y115) like traditional a7 agonists.26,27 It is possible to identify a 
cation-p interaction by progressively fluorinating the aromatic group, reducing the p 
electron density of the aromatic ring surface, and thus weakening the interaction. When 
plotted against calculated cation-p binding energies, this results in a “fluorination” plot. 
This approach also applies to other deactivating substituents on the aromatic side chain, 
including cyano and bromo functional groups. However, fluorination affects the pKa of the 
hydroxyl functional group of tyrosine as well as the strength of the cation-p interaction. 
Therefore, to study tyrosine residues, such as TyrA, it is necessary to either methylate the 
hydroxyl group, producing TyrOMe, or remove the hydroxyl group entirely and use Phe 
derivatives. 
NS6740 does form a cation-p interaction with TyrA (Table 2.1, Figure 2.4). The 
fluorination plot shows a linear relationship. The slope of the fluorination plot (-0.16 ± 
0.03) is similar to that of acetylcholine (-0.15 ± 0.02) at TyrA for a7.25 This suggests a 
similar strength of interaction, despite the increased bulkiness of the ligand. Using 
acetylcholine, we have previously shown that a sterically significant substituent is needed 
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at the 4-position of the A-site residue.25,27 This effect is less pronounced for NS6740 but 
still noticeable, with Phe and 4-F-Phe not falling on the line. 
 
Figure 2.4: Cation-p plot for TyrA in the a7 nAChR. TyrA shows a cation-p interaction with silent agonist 
NS6740 in the presence PAM PNU-120596. The similar slope of the linear regression analysis of the 
Log10[Fold Shift] to ACh indicates a similar strength interaction (NS6740, -0.16 ± 0.03 and ACh -0.15 ± 
0.02). The downward shift is because of the removal of the TyrA hydrogen bond resulting in an across the 
board gain of function for TyrA mutations in the presence of NS6740 nor the agonist ACh. ACh data is 
adapted from Marotta et al..25 
A novel observation is that TyrA forms a functionally relevant hydrogen bond for 
activation of NS6740. A large gain of function was observed when Tyr was replaced by 
TyrOMe (Table 2.1). The hydroxyl group of TyrA can act as both a hydrogen bond donor 
and acceptor. Methylation of the hydroxyl group removes the hydrogen bond donating 
ability of the residue but not its hydrogen bond accepting ability. Note that activation by 
ACh is unaffected by the Tyr-to-TyrOMe mutation, both in the presence or absence of 
PNU-120596.25 While our lab has observed a loss of function for this mutation before,28–
30 most notably in muscle type nAChR, this is the first time we have ever seen gain of 
function for TyrOMe. 
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Table 2.1: EC50 Values of Aromatic Box Residues in α7 for NS6740 + PNU-120596 (10 µM) 
Mutation 
EC50 
(nM ± SEM)     Hill (± SEM) Imax (µA) 
Fold Shift 
From WT n 
WT 62 ± 4.5 1.9 ± 0.21 0.24-2.4 - 13 
TyrA          
   TyrOMe 3.6 ± 0.19 3 ± 0.41 0.33-34 0.06 10 
   3-F1TyrOMe 9.2 ± 1.1 2 ± 0.41 0.19-25 0.15 11 
   3,5-F2TyrOMe 12 ± 1.4 2 ± 0.41 0.43-39 0.20 12 
   4-BrPhe 7.2 ± 0.41 2.7 ± 0.31 0.13-25 0.12 13 
   4-CNPhe 71 ± 2.8 3.1 ± 0.27 2.9-32 1.20 13 
   2,3,5,6-F4TyrOMe 1300 ± 110 3.4 ± 0.74 0.01-1.6 21 10 
   Phe 9.1 ± 0.4 2.9 ± 0.34 1.2-16 0.15 14 
   4-MePhe 12 ± 0.56 2.5 ± 0.28 0.01-0.29 0.19 13 
   4-F1Phe 190 ± 7.7 2.1 ± 0.15 0.13-2.7 3.10 13 
TrpB          
   Trp 66 ± 3.5 2.4 ± 0.25 0.06-0.46 1.10 13 
   Wah 13 ± 0.67 2.6 ± 0.33 7.9-43 0.20 12 
   F3-Trp 340 ± 10 2.3 ± 0.12 0.02-6.8 5.50 14 
TyrC2          
   Phe 60 ± 9.1 2 ± 0.33 0.01-0.41 0.96 13 
   TyrOMe 46 ± 2.8 2.2 ± 0.26 0.01-0.08 0.74 10 
   4-F1Phe 85 ± 9.5 1.9 ± 0.32 0.01-0.02 1.40 11 
   3-F1TyrOMe 160 ± 8.5 2.3 ± 0.17 0.01-0.27 2.70 13 
   3,5-F2TyrOMe 160 ± 12 2.7 ± 0.43 0.01-0.12 2.50 11 
   4-BrPhe 38 ± 7.1 1.6 ± 0.26 0.02-0.13 0.60 10 
TrpD          
   Trp 90 ± 6.8 1.8 ± 0.22 0.01-0.15 1.40 13 
   F3-Trp 9.2 ± 0.37 3.1 ± 0.39 0.53-9.5 0.15 12 
Leu 114          
   Leu 78 ± 7.4 2.9 ± 0.2 0.04-12 1.3 18 
   Lah 88 ± 5.5 1.6 ± 0.024 0.01-0.60 1.4 8 
Ser172          
   Thr 57 ± 4 1.8 ± 0.21 1.2-44 1 11 
   Tah 500 ± 33 2.6 ± 0.31 0.66-41 7.6 16 
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The shift in EC50 was accompanied by an increase in relative efficacy for the 
NS6740/PNU-120596 combination, being 1.9±0.32 for the TyrOMe mutant vs. 
0.027±0.004 for the wild type, relative to activation by ACh (Table 2.2). A comparable 
effect was not seen when judging the impact of PNU-120596 on ACh activation – wild 
type and the TyrOMe mutant show only a small difference. 
 
Table 2.2: Relative Efficacy to Imax Acetylcholine for NS6740 Co-Applied with Type 1 and 2 
PAMs at α7 (SEM) 
Method Drug  WT n TyrA TyrOMe n 
PEAK Height NS6740 NR  0.13 ± 0.1 15 
 ACh 1.00 ± 0.039 19 0.325 ± 0.056 16 
 NS6740+PNU-120596 0.027 ± 0.004 19 1.9 ± 0.32 16 
 ACh 1.25 ± 0.10 19 0.60 ± 0.071 16 
 NS6740+Genistein NR  0.13 ± 0.4 15 
      
Area NS6740 NR  0.34 ± 0.053 16 
 NS6740+PNU-120596 0.49 ± 0.093 18 21 ± 6.9 17 
  NS6740+Genistein NR  1.33 ± 0.3 15 
 
The increase in efficacy for the TyrOMe mutant was so great, we hypothesized that 
the PAM PNU-120596 may no longer be needed for NS6740 to open the channel (Table 
2.3, Figure 2.5). This proved to be true, as NS6740 acts as partial agonist on the mutant 
channel with an EC50 of 150 ± 22 nM. The shape of the signal changed in the absence of 
PNU-120596 to resemble a much more traditional a7 agonist trace, which is characterized 
by its sharp peak and fast desensitization (Figure 2.5). This is understandable, given that 
PNU-120596 acts by disrupting the desensitized state, resulting in broader signals when 
co-applied with an agonist.  
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Figure 2.5: Effect of the a7 TyrA TyrOMe mutation on NS6740 activity. A) EC50 curve for application of 
NS6740 on a7 TyrA TyrOMe without any type 2 PAM. B) Representative current traces for NS6740 on a7 
TyrA TyrOMe. C) Representative current traces for NS6740 on a7 wild type receptors. 
During efficacy experiments, no suppression of signal for applications of ACh after 
application of NS6740 were observed for wild type receptors in contrast to previous work, 
which indicated NS6740 had a slow binding off rate.18 This is most likely due to variations 
in experimental set-up. However, for the TyrOMe mutation a significant decrease in the 
efficacy of ACh after application of NS6740 was observed (Table 2.2). This indicates that 
TyrOMe may lower the binding off rate for NS6740. 
 
Table 2.3: EC50 Values at TyrA:TyrOMe 
Drug EC50 (nM ± SEM) Hill (± SEM) Imax (µA) n 
NS6740 150 ± 22 1.7 ± 0.37 0.052-1.8 10 
NS6740+PNU-120596 3.6 ± 0.19 3 ± 0.41 0.33-35 10 
NS6740+Genistein 8.4 ± 0.75 1.6 ± 0.16 0.22-7.2 12 
 
To further explore the effect of the TyrA TyrOMe mutation on the partial agonist 
activity of NS6740 we investigated the co-application of NS6740 with genistein, a type I 
PAM for a7. Type 1 PAMs, like genistein, are believed to bind in the same transmembrane 
region as PNU-120596 but do not destabilize the desensitized state and instead only 
increase peak current. Double mutant cycle analysis using acetylcholine established that 
like PNU-120596, genistein doesn’t alter the binding site, at least for the TyrA TyrOMe 
mutation (Table 2.4). Co-application of NS6740 and genistein at wild type receptors did 
not produce an appreciable current. For the TyrA TyrOMe mutant, genistein shifted the 
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EC50 curve and generated a broader signal both effects similar to what is seen with PNU-
120596 (Table 2.3). No increase in efficacy was observed using standard peak height 
analysis but efficacy did increase as a measure of the area under the curve an alternative 
measure sometimes used for a7 because of its fast desensitization (Table 2.2). Efficacy 
experiments were hampered by low currents of NS6740 at TyrA TyrOMe which 
necessitated testing efficacy at EC100; normally type I PAMs are screened at concentrations 
lower than EC50 to allow for observation of full potentiation. 
Table 2.4: EC50 Values and Coupling Constants for Genistein and ACh  at TyrA   
Mutation 
EC50 (µM ± 
SEM) Hill (± SEM) Imax (µA) 
Fold Shift 
From WT n 
WT 120 ± 8 1.8 ± 0.2 1.1-23 - 20 
TyrA: TyrOMe 130 ± 8 2.3 ± 0.23 2.9-48 1.1 10 
 
2.2.3  Characterization of other potential cation-p binding interactions of NS6740 in 
the orthosteric binding site  
Previous work has shown that the high affinity agonist epibatidine makes a cation-
p interaction with TyrC2 (Y217) at a7 in addition to the cation-π interaction at TyrA.27 
Low currents (Table 2.1) prevented a complete study of TyrC2; no signal was detected for 
more strongly perturbing residues such as 4-CNPhe or 2,3,5,6-F4TyrOMe. However, it is 
still clear that NS6740 does not make a strong cation-p interaction (Figure 2.6); the most 
perturbing residue measured, 4-BrPhe, was essentially wild type.  
Acetylcholine also does not form a cation-p interaction at TyrC2, but two trends 
were noted. First, bulk is required at the 4 position for ACh binding.25 This is not true for 
NS6740 - Phe and TyrOMe have similar fold shits, 0.96 and 0.74 respectively. This may 
be because NS6740 is bulkier and compensates for the loss of bulk at the 4 position. 
Secondly, TyrC2 is sensitive to 3- or 5- substitutions on the ring system for ACh binding.25 
This is also true for NS6740; the largest losses of function at TyrC2 were for 3-F1TyrOMe 
and 3,5-F2TyrOMe. However, the magnitude of the effect was much smaller 
(approximately 2.5-fold for NS6740 compared to greater than 10-fold for ACh). Again, the 
bulk of the silent agonist may explain this. Overall, interaction of NS6740 with TyrC2 does 
not appear to play an important functional role. 
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 The remaining members of the aromatic box were also probed and NS6740 was 
found not to make meaningful interactions with any of the other residues screened. 
Insertion of the highly perturbing residue F3-Trp at TrpB (W171) resulted in a modest 5.5-
fold shift (Table 2.1) indicating, at best, a very weak interaction. Substitution by F3-Trp at 
TrpD (W77) showed a slight gain of function, consistent with observations for 
acetylcholine binding to a7 (Table 2.1).25 TrpD has never been implicated in a cation-p 
interaction with an agonist in any nAChR.26 TyrC1 (Y210), the final aromatic residue that 
composes the classical binding box, was not probed, because historically any perturbation 
at this site in a7 has resulted in very large losses of function,27 and it has never been 
implicated in a cation-p interaction in any Cys-loop receptor.26  
 
Figure 2.6: Cation-p plot for TyrC2 in the a7 nAChR. TyrC2 shows no cation-p interaction with silent 
agonist NS6740 nor the agonist ACh. ACh data is taken from Marotta et al.25  
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2.2.4   Characterization of backbone hydrogen bonding to NS6740 at the orthosteric 
binding site  
Next we looked at important backbone hydrogen bonding interactions within the 
orthosteric binding site. Incorporation of a-hydroxy analogs at appropriate locations 
eliminates the hydrogen bond donating backbone NH and weakens the hydrogen bonding 
ability of the carbonyl (i-1) by converting it to an ester (Figure 2.2). This assay allows for 
the study of functionally relevant hydrogen bonds only: crystal structures may show the 
presence of a hydrogen bond but EC50 will only shift if the hydrogen bond is functionally 
relevant.  
Like with other non-quaternary amine cation agonists a hydrogen bond between 
NS6740 and the carbonyl of TrpB was observed. (Table 2.1, S172). Second, L141 has been 
shown to acts as a hydrogen bond donor for epibatidine but not acetylcholine or 
varenicline.31 NS6740 does not make a functionally relevant hydrogen bond at this site 
(Table 2.1). Finally, the carbonyl of S170 was shown to act as a hydrogen bond acceptor. 
A significant gain of function was observed when the residue (i+1) was mutated to the 
corresponding hydroxy acid (Table 2.1, TrpB Wah). This is consistent with previous work 
on a7.25 
 
2.3   Discussion 
This work focuses on the binding interactions of the silent agonist NS6740 at the 
a7 nAChR. Noncanonical amino acids were used to probe the orthosteric site, and the 
results for NS6740 — in the presence of the Type 2 PAM PNU-120596 — were compared 
to the endogenous agonist ACh. This resulted in three major findings: first, we confirmed 
that NS6740 binds at the orthosteric site; second, TyrA forms a hydrogen bond that 
discourages activation in the presence of NS6740, and this hydrogen bond is a requirement 
for silent agonist activity; and third, NS6740 forms a cation-p interaction with TyrA, 
consistent with several agonists of a7.  
It was predicted that NS6740 binds at least partially in the orthosteric binding site, 
given that NS6740 contains a cationic nitrogen at physiological pH and is a competitive 
inhibition of the native agonist.21 Using noncanonical amino acids to probe binding 
interactions of the orthosteric binding site, we showed that NS6740 does indeed bind at the 
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orthosteric binding site. This is evidenced by the cation-p interaction to TyrA and hydrogen 
bonds to TyrA and to the backbone carbonyl of TrpB. This is the most direct evidence so 
far concerning the binding site of NS6740. Furthermore, we observe subtle differences in 
those interactions that give insight into the nature of silent agonist binding.    
An intriguing finding of the present work is the key role of a hydrogen bond 
involving the OH of TyrA as the donor. This was revealed by the strong gain of function 
for the TyrOMe mutation, an effect not seen with this substitution in any other study. This 
relatively subtle mutation profoundly impacts receptor response to NS6740, turning the 
silent agonist – which produces no signal on its own – to a conventional partial agonist. 
Additionally, removal of the Tyr OH appears to lower the binding off rate for NS6740 
which further indicates an altered binding site. In principle, the hydrogen bond acceptor 
could be another residue side chain, the protein backbone, or the silent agonist itself. We 
propose that the most likely hydrogen bonding partner is the amide carbonyl of NS6740. 
Related compounds lacking the amide carbonyl, but maintaining a similar overall structure, 
have been reported in the literature as partial agonists of a7,19 supporting the importance 
of the carbonyl of NS6740 to its silent agonist activity. Secondly, the distance between the 
cationic nitrogen and carbonyl of NS6740 is ~5.9Å. While there is some variability, a 
typical distance observed in x-ray crystal structures between the backbone carbonyl of 
TrpB, which also makes a hydrogen bond to ligand, and the TyrA OH is 5.8Å, as seen the 
in the antagonist MLA bound and apo crystal structures of the a7-AChBP chimera.32,33 
This suggests that the receptor could easily adapt to an arrangement such as shown in 
Figure 2.7. It is probable that the hydrogen bond between the carbonyl of NS6740 and the 
OH of TyrA locks the receptor in a closed or an alternative desensitized state (D*). 
Removal of the TyrA OH, as in the case of TyrOMe, removes this interaction and turns 
NS6740 into a partial agonist possible by allowing the binding box to shift or contract. X-
ray crystal structures of a7-AChBP chimera with full agonists bounds have a shorter TyrA 
OH to TrpB distance (5.0 Å).32,34   
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Figure 2.7: Scheme of purposed binding interactions of NS6740 at the orthosteric binding site of a7 nAChR. 
Showing a hydrogen bond and a cation-p interaction to TyrA and a hydrogen bond to TrpB  
 
Figure 2.8 presents a simplified model to describe the energy landscape of receptor 
activation based on the observed binding of NS6740 to mutated receptors. ACh stabilizes 
the open state (O), enabling channel activation. In the a7 nAChR, the desensitized state D 
is readily reached via either the open or the closed ACh-bound state (the latter path is not 
shown in Figure 2.8). A silent agonist such as NS6740 is thought to stabilize an alternative 
desensitized state, D*, which cannot gate.18 Addition of a type II PAM such as PNU-
120596 destabilizes D* and/or stabilizes an alternative open state, O*, allowing channel 
gating. The TyrA to TyrOMe mutation results in a sharp peak (Figure 2.8), typical of 
normal agonist activity and fast desensitization, indicating that removal of the hydrogen 
bond results in NS6740 stabilizing a more typical open state and acting on its own as a 
partial agonist. Figure 2.8 shows the mutation acting in a manner similar to that of ACh, 
but other mechanisms are possible.  
Attempts to further characterization the effect of the TyrOMe mutation on the 
nature of observed open state using the type I PAM genistein proved inconclusive. Type I 
PAMs, such as genistein, do not affect the D* state and instead increase peak conductance 
through other mechanisms possibly lowering the barrier to the traditional O state.10,35 When 
co-applied with NS6740, genistein did not open wild type receptors confirming that type I 
PAMs do not affect the D* state. Genistein did acted as a PAM shifting the EC50 
dramatically for TyrA TyrOMe receptors however efficacy as measured by peak height did 
not alter. If Genistein had resulted in significant increase in peak conductance it would 
have supported the theory that NS6740 bound to the TyrA TyrOMe mutated receptor 
access the traditional O state. However, it is impossible to rule out the theory because, 
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given the experimental need to use a saturating does, any increase in peak conductance 
would have been small and may have been lost to noise. Genistein did significantly 
broadened the peak and this was reflected by an increase in efficacy as measured by area. 
Peak broadening is a7 is a sign of an altered desensitized state typically associated with 
type II PAMs such as PNU-120596. Genistein may have some type II PAM like 
macroscopic qualities: a review of the literature showed that the distinction between type I 
and II PAMs is not clear cut and PAMs have been identified that exhibit intermediate type 
I/II macroscopic properties.36–39  
 
Figure 2.8. Schematic summarizing the energy landscape for receptor activation based on the results 
described here. The scheme is based in part on previously published models of Papke.18 Shown are the 
conventional closed (C), open (O), and desensitized (D) states, as well as alternative desensitized and open 
states (D* and O*) that are accessed by a silent agonist.  
 
The final major finding is that, like all agonists tested at a7, NS6740 forms a cation-
p interaction to TyrA. A typical dependence of EC50 on the cation-π binding ability of the 
residue at the TyrA position is seen (Figure 2.4). A caveat is that, when probing for a cation-
π interaction at TyrA, we have altered the OH of the Tyr so that the hydrogen bond of 
Figure 2.7 does not form. It is conceivable that this change turns on a cation-π interaction 
that is absent in the wild type receptor. We consider this unlikely, since no other aromatic 
residue shows a cation-π interaction, and a cation-π interaction to TyrA is a universal 
feature of compounds that activate the a7 nAChR.  
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We have used noncanonical amino acids and nonsense suppression to probe the 
binding of NS6740, a silent agonist. This was the first structure-function study of a silent 
agonist, and we showed that a specific hydrogen bond inhibits agonist activity and is 
important for suppressing channel opening for silent agonists.  Given these results, in the 
future it may be possible to probe the desensitized state using nonsense suppression and 
silent agonists. 
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2.4 Materials and Methods  
Molecular Biology. The rat nAChR a7 subunit (pAMV vector), Ric3 (pAMV vector), and 
NACHO (pAMV vector), were used as the bases for all constructs. Residue numbering was 
based on the full-length protein containing the signaling sequence as found on the UniProt 
database (Q05941). Site directed mutagenesis was performed by PCR using the Stratagene 
QuikChange protocol with primers from Integrated DNA Technologies. The circular 
cDNA plasmids were linearized with NotI-HF (New England BioLabs) and purified 
(Qiagen). DNA was then transcribed in vitro using the T7 mMessage Machine kit 
(Ambion) and the mRNA was isolated using the RNeasy purification kit (Qiagen). The 
Amber (UAG) stop codon was used for incorporating noncanonical amino acids in the a7 
subunit. The 74-nucleotide THG73 tRNA and 76-nucleotide THG73 tRNA were in vitro 
transcribed using the MEGAshortscript T7 (Ambion) kit and isolated using CHROMA 
SPIN DEPC-H2O columns (Clontech).  Final concentrations were determined by UV-Vis.  
Oocyte Preparation and Injection. Xenopus laevis oocytes (stage IV and V) were 
retrieved as described previously.40 For conventional mutagenesis experiments, a7 and 
Ric3 mRNA were mixed 1:1 by weight and oocytes were injected with 50 nL solution 
containing 20 ng mRNA. Cells were incubated at 18 °C for 24 hrs in ND96 solution (96 
mM NaCl, 1.8mM CaCl2, 2 mM KCl, 1mM MgCl2, 5 mM HEPES at pH 7.5) enriched 
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with theophylline (6.7 mM), sodium pyruvate (2.5 mM) and kanamycin (0.1 mg/ml). 
Kanamycin was used because other antibiotics have been shown to reduce a7 expression 
levels.41 
Noncanonical amino acid incorporation. The NVOC protected, cyanomethylester form 
of the noncanonical amino acid was coupled to the dinucleotide dCA and enzymatically 
ligated to the UAG-suppressor 74-mer THG73 tRNACUA. The product was verified via 
matrix assisted laser desorption/ionization (MALDI) time of flight mass spectrometry 
using a 3-hydroxypicolinic acid matrix.40 The noncanonical amino acid-coupled tRNA was 
deprotected with a M365LP1 365 nm 1150 mW LED lamp (Thor Labs) immediately before 
co-injection with mRNA containing a UAG mutation at the site of interest. mRNA and 
tRNA were injected in a 1:1 or 2:1 volume ratio in a total volume of 50 or 75 nL 
respectively so that cells were injected with a 40 ng 1:1 mixture of a7-UAG and Ric3 
mRNA. For noncanonical amino acids that showed little or no response after 24 hr 
incubation, oocytes were subjected to a second round of injection and incubation as before. 
If this procedure was not effective, oocytes were double injected with a 75nL solution 
containing 40 ng mRNA of a7-UAG, Ric3 and NACHO 1:1:1 mixture. A read-through/ 
reaminoacylation test served as a negative control. Full length unacylated 76-mer tRNA 
was co-injected with mRNA. Lack of current showed no detectable reaminoacylation at 
the suppression site.  
Drug Preparation. Acetylcholine chloride (Sigma-Aldrich) was dissolved in ND96 Buffer 
to make a 1M stock solution. NS6740 was synthesized as described previously21 and 
dissolved in DMSO to form a 20 mM stock solution. PNU-120596 (Selleckchem) was 
dissolved in DMSO to 150 mM stock. Further dilutions were made for experimentation 
using ND96 Buffer.   
Electrophysiology. Agonist-induced currents were recorded using an OpusXpress 6000A 
(Axon Instruments/ Molecular Devices) in TEVC mode at a voltage clamped holding 
potential of -60 mV. Voltage and current electrodes were filled with 3M KCl. Oocytes were 
perfused with ND96 media at a rate of 3 ml/minute. Drug applications consisted of co-
application of 1 mL dose of drug solution over 8 seconds followed by a 15 second pause 
to allow response to reach maximum before being washed out for 300 seconds at a rate of 
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3 ml/min. Concentrations of NS6740 were varied over several orders of magnitude to 
generate a dose-response curve. For efficacy experiments 1 mL of EC100 dose of drug was 
applied over 8 seconds followed by a 1 minute incubation followed by 10 minute washout.    
Data Analysis. Data were sampled at 50 Hz and then low pass filtered at 5Hz. For NS6740 
co-applied with PNU-120596 EC50 measurements were recorded as peak height. Data for 
dose response curves were baselined, and normalized on a per cell basis, and then averaged 
on a per-concentration basis and fit to the Hill equation using Prism 6 (GraphPad Software). 
For relative efficacy experiments ACh doses were normalized to an initial ACh does and 
all other drug applications were normalized to an immediately preceding acetylcholine 
dose and reported as Rmax=Imax(drug)/Imax(ACh). In data tables N refers to the total number 
of oocytes analyzed. Cells from different frogs on at least two different days were used for 
each point. EC50 and Hill coefficient errors are presented as SEM.  
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Chapter 3 
 
INTRODUCTION: PHOTOREMOVABLE PROTECTING GROUPS  
 
3.1   Motivation 
Photoremovable protecting groups (PPGs), or photocages, allow, with high 
spatiotemporal control, for the non-invasive modulation of a system and have many 
applications in chemistry, chemical biology, and medicine.1–3 Standard PPGs require UV 
light to effectively uncage. However, UV light is absorbed by tissue, causing DNA damage 
and limiting penetration depths to millimeters. Longer wavelength light penetrates much 
further into tissue without damage in what is known as the optical window between 650 
and 900 nm; 810 nm light can penetrate a human skull.4 The development of PPGs that 
function with near infrared (NIR) light has great promise in medicine as a generalizable 
method for noninvasive targeted drug delivery and with the potential to reduce off target 
side effects. Coumarin,5–7 BODIPY,8–14 quinone,15,16 and cyanine17–19 based PPGs have 
shown promise towards this end; however, there are still very few PPGs that function at 
visible or NIR wavelengths.  
The challenge in designing new visible and NIR PPGs is multifold. The organic PPG 
must be soluble in aqueous solution, biocompatible, absorb light at long wavelength and 
the reaction must occur with the available energy in high quantum yield. The energy of 
activation required fundamentally limits how far a photochemical reaction can be pushed 
into the visible spectrum. In the most common PPG, 6-nitroveratryloxycarbonyl (NVOC), 
the key photochemical step is radical bond homolysis, which has an activation energy of 
80 - 120 kcal/mol.20 NIR light (650 - 900 nm) has an available excitation energy of 44 - 32 
kcal/mol. There has been little success extending NVOC protecting groups into the visible 
spectrum.21 Alternative photochemical reactions, such as photoacids, that have smaller 
activation energies will be required to develop NIR PPGs.  
 
3.2   Photoacids 
Photoacids undergo excited state proton transfer (ESPT), typically from S1, and are 
characterized by a bathochromic shift in the absorbance and fluorescence spectra of the 
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conjugate base relative to the acid.22–24 For photoacids, photoexcitation results in the 
molecules becoming stronger acids. Hydroxyarenes, the most commonly studied class of 
photoacids, can an exhibit a drop of 5-12 pKa units in the electronically excited state, which 
corresponds, at room temperature, to an energy difference of 7-14 kcal/mol a relatively 
small energetic perturbation.25 ESPT is a reversible adiabatic process, which is 
fundamentally different from photoacid generators (PAGs) which when photolyzed 
produce an irreversible ground-state acid.  
The Förster cycle model of photoacidity is used to approximate the excited state 
acidity constant (pKa*).22 Thermodynamically, photoacidity is defined as the change in 
relative free energies of the acid and conjugate base in the excited state. The Förster cycle 
considers only the S0-S1 electronic transition energies (E0,0); in Figure 3.1 hv1 is the E0,0 
for the acid and hv2 is the E0,0 for the conjugate base. Photoaciditiy is in competition with 
fluorescence (kf), non-radiative decay (knr) as well as other quenching processes. Typically, 
E0,0 values are estimated by averaging S0-S1 and S1-S0 energy bands from the absorbance 
and fluorescence spectra of both the acid and conjugate base. The excited state pKa* is then 
derived using the Förster equation (eq. 3.1) and the relationship between the electronic 
transition energies and the change in free energy between the acid and conjugate base in 
the ground and excited states in the system (hv1 - hv2) = DE0,0 = DGa - DGa*. Estimates of 
pKa* derived from the Förster cycle model are typically within 1 pKa unit of the true pKa* 
when compared to more accurate but time consuming methods that measure rates 
directly.25    
 
Figure 3.1: Förster Cycle of Photoacidity. 
hv1 knrkf
hv2 knr'kf'
ΔGa*
ΔGa
AH* A*- + H+
AH* A*- + H+
pKa*(S1)
pKa(S0)
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																																												!"#∗ = !"# − '()*'(+,../0 = !"# − 123,3,../0																															(Eq. 3.1) 
 Mechanistically, excitation results in the intramolecular charge transfer (ICT) of 
electron density from the oxygen to the aromatic core. For this reason, 1-naphthol (2) (pKa* 
= -0.2) exhibits greater photoacidity than 2-naphthol (3) (pKa* = -2.8) (Figure 3.2) because 
substitution breaks degeneracy of naphthalene’s two singlet excited states La and Lb and 1-
naphthol stabilizes the more polar state La.22,26 Similarly, addition of electron withdrawing 
groups, such as cyano groups, at C5 and C8 where negative charge localizes in the excited 
state results in “super” photoacids (pKa* < 0).27 Computation and further experimentation 
has shown that photoacidity derives from the excess stabilization of the conjugate base 
relative to the acid in the excited state following ICT.28,29 
 
Figure 3.2: Ground state pKa and first excited state pKa* for a selection of phenol and naphthols.25  
 
3.3 Ortho-Quinone Methide 
An emerging class of photoacid dependent PPGs is based on the photogeneration 
of a quinone methide (QMs) intermediate.1,30,31 QMs are a reactive intermediate in 
chemistry and have significant biology activity.32–34 QMs react with nucleotides resulting 
in alkylation and cross linking of DNA and are implicated in the biological activity of the 
anticancer agents mitomycin,35–38 anthracyclins,39,40 and tamoxifen.41 QMs are structurally 
related to benzoquinones with one of the carbonyls replaced with a methylene making them 
much more polarized (Figure 3.3a). The polarized nature of the QM makes them very 
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reactive to nucleophilic attack at the methylene carbon, which results in rearomatization of 
the phenol (Figure 3.3b). Additionally, ortho-QMs, react with electron rich alkenes in an 
inverse electron demand Diels-Alder reaction to generate chroman derivatives (Figure 
3.3b). The reactive nature of QMs prohibits isolation and instead QMs are identified 
through transient spectroscopy such as laser flash photolysis (LFP) and by analysis of 
reaction products with nucleophiles and electron rich dienophiles. 
 
Figure 3.3: Quinone methide (QM) intermediate. a) Structure of the ortho-, meta- and para-QM b) formation 
of QM with light and reaction with nucleophiles and for ortho-QM with electron rich dienophiles in an inverse 
demand Diels-Alder. 
 
Wan investigated a series of benzophenol quinone methide precursors (QMP)s and 
showed that the quantum yield of reaction for the photochemical generation of the QM was 
inversely correlated to the distance between the carbonyl and the methylene.42 This is 
consistent with the Zimmerman ortho-meta effect43,44 and the fact that ortho-QMPs 
undergo a more efficient excited state intramolecular proton transfer (ESIPT) event. 
Transient spectroscopy showed that the lifetime of the ortho- and para-QMs were similar 
at 5-10 seconds in aqueous solution.42 The lifetime of meta-QMs is significantly shorter 
and is reminiscent of a benzylic cation emphasizing the non-Kekulé nature of the meta-
QM.42 Phenyl substitution of the methylene stabilizes the positive charge of the 
zwitterionic resonance structure of QMs increasing the lifetime of the QM. QM formation 
is accelerated in aqueous solvents relative to aprotic solvents,45 further supporting the 
zwitterionic nature of the transition state, and Hammett plots additionally indicate a degree 
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of aromaticity and charge delocalization in the transition state.46 The photodehydration of 
hydroxybenzyl alcohol derivatives to generate QMs is quite generalizable, with many bis 
aryl systems proving to be good QMPs.47–54  
Leaving group, substitution, and solvent all influence the efficiency of QM 
photogeneration. Ammonium salts are the best leaving group with reported quantum yields 
(Frxn) near one,55 (HNR3+ > HNR2 > HOR > H2O).45 Consistent with the electron deficient 
nature of the QM intermediate electron donating groups greatly improve QM formation 
while electron withdrawing groups suppress formation of the QM intermediate (Table 
3.2).46 The effects are stronger for substitution at the 5- than the 4- position presumably 
because substituents at the 5- position are linked through resonance to the formation of the 
exocyclic methylene. Additionally, electron donating groups decrease QM reactivity to 
nucleophilic attack relative to electron withdrawing groups (Table 3.3).46  
 
Table 3.1: Photodehydration of hydroxybenzyl alcohols in 1:1 MeOH:H2O showing the quantum yield of 
reaction for the methyl ether at low conversion (<20%) and the lifetime of the QM intermediate in 1:1 
MeCN:H2O.42  
 
Compound Isomer R 5rxn 6 
7 ortho H 0.23  
8 ortho Ph 0.46 5-10 sec 
9 meta H 0.12  
10 meta Ph 0.23 30 ns 
11 para H 0.007  
12 para Ph 0.1 5 sec 
 
 Popik has developed photoelimination of naphthol QMPs (NQMPs) as a class of 
PPGs and shown that they efficiently and cleanly release alcohols, amines, including 
tertiary amines, carboxylic acids, and phenols.30,31,56 Notable NQMPs were able to 
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efficiently and rapidly directly release alcohols, something that has proven problematic 
with other PPGs.31 NQMPs have also shown their utility in photolithography.57 One major 
drawback to QMPs as a photolabile protecting group is that the chromophore is preserved, 
reducing efficiency of photolysis due to internal filtering effects. Popik solved this problem 
by developing a 2,5-dihydroxybenzyl QMP that tautomerizes to a methylquinone from the 
QM.58,59   
Table 3.2: Effect of substituents on the thermal generation of ortho-QMs.46  
 
 
 
 
 
 
 
 
Table 3.3: Effect of substituents on the quenching of QM with the nucleophile H2O.46  
 
Compound R k2(H2O) M-1s-1 
18 OMe 1.9  
19 H 7.8  
20 Cl 22.8  
21 COOMe 363.0  
22 CN 1999.0  
23 NO2 25400.0  
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Compound R1 R2 T °C t1/2 (min) 
13 COOMe H 100 Stable 
14 H COOMe 100 149 
15 H H 50 115 
16 H OMe 22 11 
17 OMe H 22 4 
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Mechanistic work on hydroxybenzyl alcohols illustrates that photodehydration to 
generate a QM is a photoacid dependent process. Deprotonation of the phenol in the excited 
state is required for reactivity of a QMP: no QM intermediate is observed at pHs lower 
than the pKa* of the phenol30,42 and methoxy QMP derivatives show no reactivity.42 
Conflicting reports suggest that photogeneration of QMs under alkaline conditions from 
the conjugate base may be possible.45,60 Finally the process is insensitive to oxygen, 
indicating the reaction is from the singlet state (S1).42 After ESPT formation of the QM 
intermediate proceeds rapidly; distribution of negative charge into aromatic system of the 
excited state phenolate drives the heterolytic cleavage of the benzylic C-OH bond. The 
exact mechanism of benzylic C-OH bond cleavage is not fully established and may be 
substrate and solvent dependent (Figure 3.4). Cleavage may be concerted with ESPT in the 
excited state or dehydration may occur in the ground state after proton transfer.48,61,62 An 
oxetane intermediate forms before ring opening to the QM for naphthalol ortho-QMPs with 
poor leaving groups.30 This is also true for thio-o-quinone methides,63,64 but computation30 
and experimental studies42 suggest that the oxetane intermediate is not on the reaction path 
for ortho-hydroxybenzyl alcohol despite being identified at cryogenic temperatures.65,66 
More recently an alternative mechanism has been proposed for some anthracene QMPs; 
photoionization and deprotonation result in a phenoxyl radical, and subsequent homolytic 
cleavage of the OH leaving group generates the QM.67  
 
	   
Figure 3.4: Mechanistic steps in QM photogeneration.  
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We were excited that about the possibility of extending the wavelength of QM 
formation into the visible and possibly the NIR because of the proposed two-step nature of 
the photochemical process; ESPT followed by ground state dehydration is more 
energetically favorable at long wavelengths than a concerted mechanism. Previous efforts 
to extend the wavelength of irradiation have focused on extending the cyclic aromatic core; 
irradiation of an anthracene QMP at 420 nm resulted in photodehydration to yield the 
ortho-QM (Frxn = 0.023 ± 0.001).68  One possible concern with increasing electronic 
conjugation is it also lowers the energy of first triplet state (T1) and increases the efficiency 
of intersystem crossing (ISC) reducing QM generation.68,69 However, Freccero showed that 
with the right geometry and leaving group QM formation could be favored over ISC and 
singlet oxygen sensitization.69 Continued extension of the aromatic polycyclic framework 
is not practical, and therefore this thesis investigates photogeneration of QMs from model 
heteroaromatic QMPs to better design longer wavelength QMPs.  
 
3.4 Summary of Work: Part Two 
In the second part of this dissertation two classes of photochemical reactions were 
investigated in efforts towards rationally design longer wavelength PPGs. Chapter IV 
investigates a series of quinoline and quinolinium QMPs for photochemical reactivity: 3-
(hydroxymethyl)quinolin-4-ol was found to be photostable, however both 4-
(hydroxymethyl)quinolin-3-ol and 2-(hydroxymethyl)quinolin-3-ol were found to form 
QM intermediates when irradiated under neutral aqueous conditions. The reactivity was 
pH dependent and under acidic conditions photogeneration of QM intermediates was 
quenched; positively charged quinolinium derivatives also did not show any photochemical 
reactivity. Chapter V describes efforts towards improving the efficiency of quinone 
photoreduction through a radical decarboxylation. A glycine moiety was installed on two 
different quinones; both proved to be photostable.   
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Chapter 4 
 
PHOTOCHEMISTRY OF QUINOLINE AND QUINOLINIUM  
ORTHO-QUINONE METHIDE PRECURSORS 
 
Abstract 
The photochemical dehydration of ortho-hydroxybenzyl alcohols, through 
the formation of quinone methide (QM) intermediates, is an emerging 
strategy for photoremovable protecting groups for alcohols, amines, and 
carboxylic acids. Little is known about the tolerance of the reaction to 
substitution of the aromatic core, a necessary step towards extending the 
wavelength of reaction. This chapter looks at the photoreactivity of 
quinoline and quinolinium QM precursors (QMPs) and shows that 2-
hydroxymethyl-3-quinolinol (13a) and 4-hydroxymethyl-3-quinolinol 
(10a) derivatives both form QMs when irradiated under neutral aqueous 
conditions. This photochemistry is pH dependent, and it appears that 
quinolinium QMPs do not undergo photodehydration to the QM 
intermediate. 
 
4.1   Introduction 
The ortho-quinone methide precursor (QMP) protecting group for alcohols, 
amines, and acids1–7 is a little used photolabile protecting group that has the potential to 
work at longer wavelengths and potentially in the NIR (Figure 4.1a,b). The initial 
photochemical step, ESPT, has a small energy of activation of between 7-14 kcal/mol, and 
is followed by heterolytic cleavage of the benzylic leaving group bond.3,8 The minimum 
requirements for a QMP are a conjugated hydroxymethyl, -CH2OH, and a phenol, though 
there is significant variation in reaction effectiveness depending on the isomer,8 
substituents,9,10 leaving group11,12 and overall geometry of the conjugated system.8,13–15 
Extension of the quinone methide (QM) photochemistry to longer wavelengths should be 
possible by instillation of the requisite functionality onto a known long wavelength 
absorbing dye such as a cyanine dye.  
In cyanine dyes two heteroaromatic nitrogens are linked by a polymethine 
chain.16,17 Inclusion of a QMP at one or both termini of the cyanine dye could potentially 
furnish a long wavelength photochemical QMP (Figure 4.1c). Given the synthetic 
complexity of installing the functionality required for an ortho-QMP and the number of 
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possible long wavelength cyanine frameworks, there is a need for short wavelength model 
studies to better understand the tolerance of the photochemical QM reaction to substrate 
modification. This chapter focus on quinoline and quinolinium based QMPs, modest 
perturbations introducing a heterocyclic aromatic core and a positively charge heterocyclic 
aromatic core respectively. Quinolinium based cyanine derivatives are known.16  
 
Figure 4.1: ortho-Quinone Methide (ortho-QM). A) scheme showing the ortho-QM photochemical 
protecting group. B) Naphthol based QM precursors (QMPs) that have been developed as protecting 
groups. C) Example of a potential cyanine based longer wavelength QMP. D, E) Known pyridine based 
heterocyclic QMP systems.  
 
There are two previous examples in the literature of shorter wavelength 
heterocyclic QMPs, including pyridoxine 5 (vitamin B6)18 and a Mannich base bipyridyl 
QMP 319 (Figure 4.1d,e) but no examples of a QMP with a charged aromatic core. 
Photolysis of pyridoxine 5 is known to generate a QM group under aqueous conditions. 
Despite the presence of hydroxymethyl, -CH2OH, groups, ortho and meta only the ortho-
QM has been detected experimentally.18 Computational studies suggest that for pyridoxine 
5 excited state dehydroxylation is favored over ground state for QM formation — a 4 
kcal/mol reaction barrier compared to a 20 kcal/mol reaction barrier — and in S1 the energy 
barrier for photogeneration of the ortho-QM is 8 kcal/mol lower than for the meta-QM 
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accounting for the selectivity of the photolysis reaction.20 The quantum yield of ortho-QM 
formation is about half that of the comparable benzylic QMP 2-
(hydroxy(phenyl)methyl)phenol (2) under similar conditions (Frxn = 0.2 for QMP 618 vs 
Frxn = 0.46 for QMP 28 in 1:1 MeOH:H2O at 254 nm). Introduction of an additional pH 
sensitive functional group may alter the reaction pathway or the nature of the intermediate: 
transient spectroscopy showed two ortho-QM species at pH 7, a protonated QM, the result 
of ESPT to the nitrogen and a neutral QM, the result of ESPT to either the leaving group 
or bulk solvent.18  
This chapter explores a series of quinoline QMPs and shows that regional isomers 
display marked differences in reactivity. This chapter also investigates the photochemistry 
of quinolinium QMPs for the first time and demonstrates that the positively charged 
electron withdrawing quinolinium functionality severely inhibits QMP reactivity. 
 
4.2   Quinoline ortho-quinone methide:  
4.2.1 Synthesis of quinoline derivatives: 
Three quinoline based ortho-QMPs were synthesized and their photochemistry was 
investigated. Ortho-formylation of 4-hydroxyquinoline (8) with formic acid produced the 
desired quinoline 9 in a single step (Scheme 4.1).  
 
Scheme 4.1: Synthesis of 3-(hydroxymethyl)quinoline-4-ol (9) 
 
Quinoline 10a was furnished in two steps form the commercially available 
quinoline acid 11 (Scheme 4.2); direct reduction of quinoline 11 resulted in low yields and 
a mixture of products due to the poor solubility of 11 in organic solvents. Instead 11 was 
esterified using coupling reagent EDCI and then ester 12 was easily reduced to the desired 
diol 10a with DIBAL. Heating of diol 10a in the presence of an alcohol or amine resulted 
in the derivatives 10b and 10c presumable via a thermal ortho-QM; interestingly acid 
catalysis shut down this reaction.   
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Scheme 4.2: Synthesis of 4-(hydroxymethyl)-2-methylquinolin-3-ol (10a) 
 
Initial attempts to synthesize quinoline 13a, were unsuccessful. As had been 
reported in the literature21 direct synthesis of 2- substituted 3-quinolinol derivatives using 
the Friedlander condensation was found to be challenging. Similarly a derivatization 
method starting with the commercially available 3-quinolinamine, adapted from Riego et 
al.,22 was not reproducible. Specifically, a two-step oxidation by selenium dioxide followed 
by hydrogen peroxide proved very low yielding (< 15 %) and inconsistent. Instead 
quinoline 10a was successfully synthesized by adaption of a protocol from Vippila et al 
(Scheme 4.3).23 Selective reduction of 2-nitrobenzaldehyde (14) with iron furnished 2-
aminobenzaldehyde (15) and subsequent condensation with ethyl bromopyruvate  provided 
the amino quinoline 16. A Sandmeyer reaction converted the amine 16 to hydroxy 
quinonline 17 and subsequent reduction with DIBAL furnished 13a reliably in 4 steps. 
Heating the diol in the presence of alcohol resulted in the derivative 13b. The amine 
substituted 13c was synthesized directly from 3-quinolinol (18) by Mannich reaction using 
Eschenmoser's salt (Scheme 4.3).19 
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Scheme 4.3: Synthesis of 2-(hydroxymethyl)quinoline-3-ol (13a) 
 
4.2.2 Photophysics  
UV-vis spectra of quinoline 10a and 13a are similar and resemble the spectrum of 
3-quinolinol (18) at pH 7 (Figure 4.2).24 In aqueous solution compounds 10a and 13a 
contain two major UV-vis bands above 300 nm: at lmax = 320 nm and 375 nm for 10a and 
lmax = 325 nm and 370 nm for 13a but the relative intensities are opposite. The two bands 
are attributed to a combination of neutral and zwitterionic species being present in 
solution.24 Both 10a and 13a show strong fluorescence (Figure 4.3). Under neutral buffered 
aqueous conditions both show a broad emission band when excited at 325 or 375 nm (lmax 
= 455 nm for 10a and lmax = 475 nm for 13a). Quinoline 10a shows significantly higher 
florescence efficiency (FFl = 0.49) than 13a (FFl = 0.26) at 325 nm excitation. 2-hydroxy-
1-naphthalenemethanol (3) also has a higher fluorescence efficiency ((FFl = 0.30)3 than 3-
hydroxy-2-naphthalenemethanol (4) (FFl = 0.23),3 but it is not as pronounced as in the 
quinoline isomers.  
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Figure 4.2: UV-Vis spectra of pH neutral phosphate buffered solution of quinoline 10a (blue) and quinoline 
13a (orange).  
 
 
Figure 4.3: Emissions spectra of neutral pH phosphate buffered solution of quinoline 10a (blue) and 
quinoline 13a (orange).  
 
The excited stare acidity of quinoline 10a (pKa* = 3.5) was estimated using Förster 
analysis (Figure 4.4a) and is slightly lower than the known pKa* of 3-quinolinol (18) (pKa* 
= 4.0).25 This is a significant drop in acidity of 4.5 orders of magnitude relative to the 
ground state pKa of 3-quinolinol (pKa = 8.06).26 The enhanced acidity of 10a is most likely 
due to the intramolecular anion-stabilizing hydrogen bond between the phenolate oxygen 
and the benzylic hydroxy group as has been observed previously in ortho-substituted 
phenols.3 Quinoline 13a exhibited a 10 nm bathchromic shift in absorbance between the 
acid and conjugate base indicative of a photoacid (Figure 4.4b). However, emission at pH 
5 occurred from the tautomeric –OQNH+ (lmax = 450 nm) under neutral conditions which 
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is red shifted compared to emission from the conjugate base (lmax = 433 nm). Rapid ESIPT 
to the nitrogen is known to outcompete fluoresce from the acid for 3-quinolinol24 and can 
be observed to some extent for quinoline 10a, which exhibits duel emission at pH 5 from 
the acid HOQN (lmax = 370 nm) and zwitterionic –OQNH+ species (lmax = 454 nm). While 
it may not be possible to accurately determine the pKa* for quinoline 13a using Förster 
analysis, quinoline 13a is certainly still a photoacid.  
 
Figure 4.4: Spectra for Förster analysis to determine excited state pKa (pKa*). A) Quinoline 10a shows a 
bathochromic shift in absorbance (solid) and emission (faded) between the acid (orange) and the conjugate 
base (blue). Emission is seen from both the acid HOQN and the zwitterion –OQNH+ at pH 5. B) Quinoline 
13a shows a bathochromic shift in the absorbance (solid) between the acid (orange) and the conjugate base 
(blue). Emission (faded) is only observed from the from the zwitterion –OQNH+ at pH 5 (orange) and not the 
acid resulting an hypsochromic shift between the acid and conjugate base in the emission. (Absorbance 
spectra (solid) and emission spectra (faded) pH 5 (orange) and pH >10 (blue)).  
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4.2.3 Photochemistry 
Quinoline 9 was photostable; irradiation in the presence methanol or ethyl vinyl 
ether (EVE) did not result in the desired ether 19 or the Diels Alder cycloadduct 20, 
respectively (Scheme 4.4a). This is most likely due to tautomerization to the quinolone 
21 species at neutral pH;27 4-hydroxyquinoline has a hydroxyl pKa of 11.74  and a 
nitrogen pKa of 2.27.28 Lack of a photoacidic proton would explain the photostability of 
6 since ESPT is required for the initial step in photo QM formation.8  
Quinoline isomers 10 and 13 are unable to tautomerize and form a quinolone 
isomer. Irradiation, at > 320 nm, of quinoline 10a in a solution of 1:1 H2O:MeOH 
resulted in a mixture of the photochemical product ether 22 and the starting material 10a 
according to LCMS and NMR (Scheme 4.4b). Water and methanol are both nucleophiles 
that can quench the ortho-QM intermediate resulting in a mixture of products. The 
reaction proceeded cleanly in the presence of oxygen, as is typical of ortho-QM 
photochemistry, and no difference in reactivity was observed between degassed and non-
degassed samples. Photolysis of 10a with EVE in 1:1 H2O:MeCN gave the Diels-Alder 
adduct 23 cleanly at low conversion; the product 23 is prone to secondary photolysis3 and 
absorbs at similar wavelengths. Formation of EVE product 23 is only possible by reaction 
of a 1,4-dipolar species with EVE and therefore provides conclusive evidence for the 
efficient generation of ortho-QM 10QM. Additionally, irradiation of quinolin-4-
ylmethanol (24) in a 1:1 H2O:MeOH did not result in any ether product (Scheme 4.4c), 
ruling out photoinduced homolytic bond cleave as a mechanism and confirming the vital 
nature of the phenol in the photochemical mechanism. Irradiation of quinoline 10b or 10c 
in 1:1 H2O:MeOH resulted in ether photoproduct 22 according to LCMS.  
The quinoline 13a exhibited similar photochemistry to 10a, and when irradiated in 
the presence of methanol or EVE the expected photoproduct was observed by NMR and 
LCMS cleanly (Scheme 4.4d). Surprisingly the amine substituted quinoline 13c appears to 
be photostable; amines are typically better leaving groups for ortho-QM reactions,11 
however this doesn’t appear to be the case. It is possible that –NMe2 or HNMe2 is a better 
nucleophile and outcompetes quenching by water or methanol: for Mannich base 7 
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reactivity was only observed with stronger nucleophiles and no hydration product was 
observed.19 However, this does not explain the lack of reactivity with EVE. 
 
Scheme 4.4: Photochemistry of quinoline QMPs. A) Quinline 9 does not from an QM when irradiated 
because it tautomerizes to quinolone 21. B) Photoreactivity of quinoline 10a. C) Quinoline 24 is 
photostable. D) Quinoline 13a forms an ortho-QM when irradiated.  
 
Quantum yields are used to compare the efficiency of photochemical reactions. 
Qualitatively the photodehydration of quinoline 10a appeared to be less efficient than the 
equivalent naphthalol QMP when the two reactions were run in parallel. This is not 
surprising given the quantum yield of benzylic QMP 2 (Frxn = 0.46)8 was double that of 
pyridine QMP 6 (Frxn = 0.2)18 under similar conditions. Attempts were made using a 
ferrioxalate actinometer to measure the quantum yield of 10a. However, issues of phase 
separation of EVE in MeCN:H2O solutions made for inconsistency in sample preparation 
and gave a range of quantum yields between 0.001 and 0.9, a meaninglessly large range.  
Without accurate quantum yields it is hard to compare the reactivity of quinoline 
10a and 13a. Given the high fluorescence efficiency of 10a it might be expected that 
quinoline 10a would have a lower quantum yield of reaction than quinoline 13a but at least 
for naphthol QMPs that logic does not hold. Naphthol 3 has both a greater quantum yield 
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or reaction (Frxn = 0.2) and fluorescence (Ffl = 0.3) then naphthol 4 (Frxn = 0.17 Ffl = 
0.23).  
Laser flash photolysis (LFP) is an effective method for direct observation of the 
ortho-QM transient which is characterized by a broad, O2 insensitive, long lived transient 
that is quenched by the addition of nucleophiles or electron rich dienophiles. Measurements 
were performed to probe for the ortho-QM intermediate of quinoline 10a. Laser pulsed 
excitation of quinoline 10a, by a Nd:YAG laser at 355 nm, resulted in a burst of bright 
fluorescence covering the region from 400 nm to 475 nm. This intense emission saturated 
the detector complicating observations in this region. A transient was observed between 
405 nm and 475 nm with a lifetime of 1.5 µs in aqueous solution (pH 7 Phosphate Buffer) 
(Figure 4.5). This lifetime was much shorter than anticipated given the lifetime of 
pyridoxine 6 (t = 10 ms)18 and bipyridyl 7 (t = 50 µs)19 and there was no observed change 
in the lifetime of the transient in the presence of the sodium azide (NaN3) or EVE, two 
common ortho-QM quenchers.  
 
Figure 4.5: Lifetime of the possible transient in pH 7 phosphate buffer (1.5 µs) and trifluorethanol (200 ns) 
at 405 nm for 10a. 
 
Worried that the solvent, water, was quenching the ortho-QM intermediate, 
experiments were carried out in trifluoroethanol (TFE) a polar non-nucleophilic solvent in 
which electrophilic species such as QMs exhibit longer lifetimes.13,29,30 Instead of 
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increasing the lifetime of the observed transient the lifetime decreased when experiments 
were conducted in TFE (200 ns) (Figure 4.5). Addition of the nucleophile NaN3 or EVE 
did not affect the lifetime of the transient (Figure 4.6). It was concluded that the observed 
transient was an artifact of the fluorescence event saturating the detector. Others have 
solved this problem by observing the transient at shorter wave lengths, < 310 nm, where 
fluorescence is not a problem;3 however, instrumentation prevented observation at 
wavelengths shorter than 400 nm. Given the limits in instrumentation it was impossible to 
determine the lifetimes of the otho-QM intermediates for quinoline 10a and 13a and 
compare them to the known lifetime of the equivalent naphthalol QMPs or other 
heterocyclic QMPs. The ortho-QM intermediate derived from hydroxybenzyl alcohols 
exhibits a three orders of magnitude longer lifetime than the ortho-QM derived from an 
equivalent heterocyclic pyridine derivative under similar reaction conditions.8,18 Similarly, 
without identification of the transient it is impossible to determine if ortho-QM formation 
occurs via a benzoxetane3 or radical mechanism,31 which have been purposed in some 
instances of photochemical QM generation.   
 
Figure 4.6: Effect of the QM quenchers ethyl vinyl ether (green) and sodium azide (blue) on the lifetime of 
observed possible transient in trifluorethanol (gray) at 405 nm for 10a. 
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4.3 Quinolinium ortho-quinone methide 
4.3.1 Synthesis of quinolinium derivatives: 
Treatment of quinoline 10a with methyl iodide resulted in an intractable mixture of 
the desired quinolinium 28 and the starting material 10a. Protected quinoline ketal 29 was 
highly soluble and when treated with methyl iodide the quinolinium 30 crashed out of 
solution making separation and purification trivial. The ketal protecting group was 
removed efficiently by refluxing under acidic conditions and the desired quinolinium 28 
was purified by HPLC with good separation (Scheme 4.5a).  
 
Scheme 4.5: Synthesis of quinolinium derivatives 28 and quinolinium 31.  
 
Given the initial difficulty is synthesizing quinoline 13a efforts focused on the 
synthesis of Mannich base derived quinolinium 13c instead. Treatment of quinoline 13c 
with methyl iodide did not result in any of the desired quinolinium according to NMR. 
Instead the much stronger methylating agent dimethyl sulfate was required to furnish 
quinolinium 31 in good yield (Scheme 4.5b). Only the single addition product was 
observed.  
 
4.3.2 Photochemistry  
Quinolinum 28 was photostable; irradiation, at > 320 nm, in a 1:1 H2O:MeOH 
solution resulted no observed photochemical product 32 according to LCMS and NMR 
(Scheme 4.6a). Similarly photolysis of 28 with EVE in 1:1 H2O:MeCN gave no Diels-
Alder adduct. Under the same conditions quinolinium 31 was also proved inert (Scheme 
4.6b). The photostability of quinoline 13c complicated analysis of the photostability of 
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quinolinum 31 and subsequent experiments on counter ion, photoacidity, and charge 
focused on quinolinum 28.  
 
Scheme 4.6: Photochemistry of quinolinium derivatives quinolinium 28 and quinolinium 31.  
 
Iodide, the counter ion in quinolinum 28, is known to promote intersystem crossing 
to the triplet and to promote electron transfer to the iodide; both mechanism would inhibit 
QM formation. Ion exchange to the non-coordinating counterions, CF3SO3-, ClO4-, BF4-, 
and PF6- did not alter the photostability of quinolinium 28. Iodide has previously been used 
as a counter ion for quaternary ammonium salt QM precursors with no observed negative 
effect on photogeneration of QMs.32–34 Similarly, acetate, chloride, and perchlorate ions 
anions had no effect on QM formation and ionic concentrations of 0.1M didn’t negatively 
impact QM formation or reactivity.35 The counterion is most likely not the source of 
quinolinum 28 photostability. 
Quinolinium 28, like other known quinoliniums,36–38 is a super photoacid with a 
pKa* less than zero. As is typical of photoacids, UV-vis spectra showed a 47 nm 
bathochromic shift between the acid (lmax = 342 nm) and the conjugate base (lmax = 389 
nm) (Figure 4.7). Indicative of a super photoacid, the emission spectra of the acid and 
conjugate base are superimposable (lmax = 477 nm) (Figure 4.7) because the rate of ESPT 
eclipses fluorescence from the excited state acid.39 Förster analysis of the UV-vis spectra 
of the acid and conjugate base indicate an approximate pKa*of -2. Using absorbance data 
alone underestimates the true pKa*40 and as the pKa* approaches zero Förster analysis 
becomes less accurate because of increasing entropic factors.41 There are no examples in 
the literature of super photoacid QMPs. If QM formation is a concerted process with ESPT 
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then the ultrafast proton transfer exhibited by super photoacids may be detrimental to QM 
formation.  
 
 
Figure 4.7: Spectra for Förster analysis to determine excited state pKa (pKa*) for quinlonium 28. A 
bathochromic shift is observed in absorbance (Solid) between the acid (orange) and the conjugate base 
(blue). The emissions spectra (faded) for the acid (orange) and conjugate base (blue) are superimposable 
indicative of a super photoacid. 
 
4.3.3 pH dependence of photochemistry 
To understand the effect of a positively charged species on QM formation, the pH 
dependence of quinoline 10a was investigated. Under acidic conditions protonation of the 
nitrogen results in a species isoelectronic with quinolinium 28. Bulk photolysis of ortho-
QMPs is typically pH independent over the pH range 2-7.3 The photolysis of quinoline 10a 
and 13a in 1:1 EtOH:citrate-phosphate buffer over the pH range 2.5-6 at low conversion 
rates showed marked pH dependence on QM formation when controlling for the dark 
thermal acid catalyzed reaction (Figure 4.8). This was more pronounced for quinoline 10a, 
which showed no photoreactivity at pH 3, than for quinoline 13a. The significant drop in 
reactivity corresponds to the nitrogen pKa (pKa = 4.3 for 3-hydroxyquinoline).26 
Protonation of the nitrogen reduces or eliminates QM formation.  
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Figure 4.8: pH dependence on the photoreactivity of quinoline 10a (blue) and quinoline 13a (red) relative 
to reactivity at pH 6.0. 
 
pH has not previously been shown to effect bulk quantum yields but it has been 
shown to affect the lifetime of the QM intermediates in solution. The lifetime of the 
pyridoxine QMP 6 derived ortho-QM was 200 fold shorter at pH 1 than in neutral 
solution.18 (Brousmiche and Wan do not report a change in bulk quantum yield of reaction 
at pH 1 for pyridoxine 6.) Similarly, the nitrogen protonated QM (t = 50 µs) was observed 
to have a much shorter lifetime than the neutral QM (t = 10 ms) at pH 7.18 The electron 
withdrawing nature of the quinolinium makes the QM much more reactive because of the 
electron deficient nature of QMs. Previously this effect was shown to be more pronounced 
when the EWD was in conjugation with the QM carbonyl9 like in the case of quinolinium 
28. QM lifetime doesn’t always correlate with the bulk quantum yield,8 and without 
transient spectroscopy it is impossible to determine if quinolinium 28 forms a very short 
lived QM intermediate. However, given that bulk photolysis resulted in no photoproduct it 
may be that the quinolinium moiety is so electron withdrawing that it prevents formation 
of the QM.  
  
4.4   Conclusions 
Quinoline derivatives can function as QMPs depending on the isomer. Quinolin-4-
ol derivatives do not make good QMPs because under neutral conditions quinoline 9 
tautomerizes to quinolone 21. The same is expected for 2-quinolinol QMPs which similarly 
tautomerize. Investigation of quinoline 10a and quinoline 13a showed that 3-quinolinol 
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derivatives do form ortho-QMs when irradiated as evidenced by their reactivity with EVE 
and nucleophiles. Quinoline 13 may not be as reactive and or stable given the lack of 
reactivity of quinoline 13c.   
The electron withdrawing nature of quinoliniums make them ill-suited as QMPs. 
This is definitely true for 3-hydroxyquinolinium where the QM carbonyl is in conjugation 
the quinolinium nitrogen. 5- or 7-hydroxyquinolium based QMPs may display better 
photochemistry since locations on the distal ring are less effected by the nitrogen and the 
QM carbonyl would not be in conjugation with the quinolinium. 
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4.6   Experimental   
4.6.1   General Procedures 
Unless otherwise stated reactions were carried out at ambient temperatures under argon. 
Any potentially light sensitive compounds were protected from light using aluminum foil 
and were carried out under low ambient light conditions. Commercially available reagents 
were obtained from Sigma Aldrich, AK scientific, Alfa Aesar, Acros Organics, or Strem 
Chemicals. Solvents used in photolysis and UV-vis experiments were EMD Millipore 
(OmniSolveÒ) grade. Other solvents were used as received unless otherwise noted. 
Reactions were monitored with thin layer chromatography using EMD/Merck silica gel 60 
F254 pre coated class plates (0.25 mm). Flash column chromatography was conducted 
using 60 A, 230-400 mesh silica gel purchased from Alfa Aesar. NMR spectra were 
recorded on Varian (300, 500, or 600 MHz) or Bruker (400 MHz) spectrometers. UV-vis 
spectra were obtained using a Cary 60 spectrometer in 1 cm pathlength quartz cuvettes. 
Photolysis experiments were conducted in quartz cuvettes or custom quartz test tubes using 
either a 300 W Hg arc lamp (66011, Oriel) with glass filters or a M365LP1 365 nm 1150 
mW LED lamp (Thor Labs).  
 
4.6.2   Synthesis  
 
3-(hydroxymethyl)quinolin-4-ol (9): Formaldehyde 37% (0.3 mL, 3.4 mmol, 2 eq) was 
added to a solution of 4-hydroxyquinoline (8) (0.25 g, 1.7 mmol, 1 eq) in 1 M NaOH aq (3 
mL). The reaction was stirred at 45 °C for 18 hours, cooled to room temperature, acidified 
with 2 M HCl (2 ml) and cooled in an ice bath. White crystals were isolated and washed 
with EtOAc (2 X 5 mL). Recrystallized from hot methanol to yield give 0.29 g (1.6 mmol) 
of 9 in 95% yield as a white solid. 1H NMR (300 MHz, DMSO-d6) δ 11.75 (s, 1H), 8.10 
(dd, J = 8.2, 1.5 Hz, 1H), 7.86 (dt, J = 6.0, 1.0 Hz, 1H), 7.62 (ddd, J = 8.4, 6.8, 1.5 Hz, 
1H), 7.57 – 7.48 (m, 1H), 7.29 (ddd, J = 8.1, 6.8, 1.2 Hz, 1H), 4.90 (t, 1H), 4.41 (d, J = 4.6 
Hz, 2H). 
 
N
OH OH
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ethyl 3-hydroxy-2-methylquinoline-4-carboxylate (12): 200 proof ethanol (15 mL, 257 
mmol, 10 eq), and DMAP (0.50 g, 4.1 mmol, 0.16 eq) were added to a suspension of 2-
methyl-3-hydroxy-4-quinolinecarboxylic acid (11) (5.0 g, 24.6 mmol, 1 eq) in DCM (100 
mL), in a 500 mL RBF. The reaction was cooled to 0 °C and EDCI (5.73 g, 30.0 mmol, 1.2 
eq) was added in 5 portions over the course of 10 minutes. Reaction was stirred for 5 hours 
at room temperature, diluted with water (100 mL), extracted with DCM (3 x 50 mL), 
washed with brine (50 mL), dried over MgSO4, and concentrated. Purified by flash column 
chromatography on silica (EtOAc:Hexane, 15:85) to give 4.32 g (18.7 mmol) of 12 in 76% 
yield as a white solid. 1H NMR (500 MHz, Chloroform-d) δ 12.04 (s, 1H), 8.63 – 8.57 (m, 
1H), 8.02 – 7.96 (m, 1H), 7.57 – 7.51 (m, 2H), 4.16 (s, 3H), 2.73 (q, J = 1.7 Hz, 2H), 1.59 
(t, J = 1.7 Hz, 3H). 13C NMR (126 MHz, Chloroform-d) δ 172.19, 155.52, 153.86, 142.27, 
129.70, 127.79, 126.25, 124.72, 123.84, 108.66, 53.04, 29.74, 20.60. 
 
 
4-(hydroxymethyl)-2-methylquinolin-3-ol (10a): A solution of quinoline ester 12 (1.00 
g, 4.34 mmol, 1 eq) in THF (20 mL) was added dropwise to DIBAL 1 M in THF (15 mL, 
15 mmol, 3.2 eq) at -78 °C. Reaction was stirred at room temperature for 4 hours and 
quenched by dropwise addition of EtOAc (20 mL) at 0 °C, followed by slow addition of 
1/2 saturated Rochelle salt aq (60 mL) at room temperature. Solution was stirred for 48 
hours at room temperature, extracted with EtOAc (6 x 50 mL), washed with brine (1 x 50 
mL), dried over MgSO4, and concentrated. Purified by flash column chromatography 
(Methanol:DCM, 5:95) to give 570 mg (3.0 mmol) of 10a in 69% yield as a white solid. 
1H NMR (400 MHz, DMSO-d6) δ 9.71 (s, 1H), 7.99 – 7.91 (m, 1H), 7.85 – 7.78 (m, 1H), 
7.53 – 7.43 (m, 2H), 5.80 (t, J = 4.7 Hz, 1H), 5.07 (d, J = 4.6 Hz, 2H), 3.34 (s, 1H), 2.55 
(s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 152.76, 147.50, 142.34, 128.82, 127.18, 126.12, 
126.07, 124.61, 123.54, 56.21, 21.32. 
N
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4-(ethoxymethyl)-2-methylquinolin-3-ol (10b): Quinoline 10a (90 mg, 0.48 mmol, 1 eq) 
was dissolved in absolute EtOH (10 mL) and heated to reflux for 24 hours. Reaction was 
cooled to room temperature, concentrated, and purified by flash column chromatography 
(EtOAc:Hexane, 20:80) to give 100 mg (0.46 mmol) of 10b in 96% yield as white solid. 
1H NMR (400 MHz, Chloroform-d) δ 9.25 (s, 1H), 7.96 (dd, J = 8.3, 1.4 Hz, 1H), 7.57 (dd, 
J = 8.2, 1.5 Hz, 1H), 7.54 – 7.39 (m, 2H), 5.23 (s, 2H), 3.77 (q, J = 7.0 Hz, 2H), 2.66 (s, 
3H), 1.37 (t, J = 7.0 Hz, 3H). 13C NMR (101 MHz, Chloroform-d) δ 152.85, 148.46, 
142.03, 129.27, 126.09, 125.99, 125.53, 120.40, 118.01, 69.34, 67.82, 29.73, 20.43, 15.06 
 
 
4-((N, N-dipropylamino)methyl)-2-methylquinolin-3-ol (10c): Dipropylamine (2.5 
mL) was added to quinoline 10a (105 mg, 0.55 mmol, 1 eq) dissolved in MeCN (12 mL). 
The reaction was heated to reflux for 3 days before being cooled and concentrated. The 
reaction was purified by flash column chromatography (Methanol:DCM, 2:98) to give 
136 mg (0.50 mmol) of 10c in 91% yield as a white solid. 1H NMR (500 MHz, 
Chloroform-d) δ 8.07 – 8.03 (m, 1H), 7.74 (ddd, J = 8.2, 1.5, 0.6 Hz, 1H), 7.53 – 7.40 (m, 
2H), 4.21 (s, 2H), 3.49 (s, 3H), 2.62 – 2.54 (m, 4H), 1.68 – 1.59 (m, 4H), 0.92 (t, J = 7.4 
Hz, 6H). 13C NMR (126 MHz, Chloroform-d) δ 152.54, 151.13, 141.86, 129.36, 127.02, 
125.88, 125.47, 120.57, 118.27, 56.37, 53.21, 20.36, 19.68, 11.87. 
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4-(methoxymethyl)-2-methylquinolin-3-ol (22): Quinoline diol 10a (50 mg, 0.26 mmol, 
1 eq) in H2O:MeOH (1:1, 220 mL) was irradiated with a 300 W Hg arc lamp (Oriel 
Instruments) using a 320 nm long pass filter and UG-II filter for 6 hours in a 300 mL Quartz 
RBF. Methanol was removed under reduced pressure and the photolysis product was 
extracted with DCM (3 x 100 mL), dried over MgSO4, and concentrated. Purified by flash 
column chromatography (Methanol:DCM, 1:99) to give 13 mg (0.062 mmol) of 22 in 24% 
yield as yellow oil. 1H NMR (300 MHz, Chloroform-d) δ 7.97 (dd, J = 8.2, 1.5 Hz, 1H), 
7.65 – 7.40 (m, 3H), 5.22 (s, 2H), 3.63 (s, 3H) 2.67 (s, 3H). 13C NMR (101 MHz, CDCl3) 
δ 152.98, 148.57, 142.15, 129.38, 126.29, 126.19, 125.67, 120.51, 117.93, 71.42, 59.67, 
20.50. 
 
 
3-ethoxy-5-methyl-2,3-dihydro-1H-pyrano[2,3-c]quinoline (23): Quinoline diol 10a 
(36 mg, 0.20 mmol, 1 eq) and ethyl vinyl ether (1.9 ml, 20 mmol, 100 eq) in H2O:MeCN 
(1:1, 200 mL) was irradiated with a 300 W Hg arc lamp (Oriel Instruments) using a 320 
nm long pass filter and UG-II filter for 7 hours in a 300 mL quartz RBF. Acetonitrile was 
removed under reduced pressure and product was extracted with EtOAc (3 x 100 mL), 
washed with water (1 x 50 mL) and brine (1 x 50 mL), dried over MgSO4, and concentrated. 
Purified by flash column chromatography (EtOAc:Hexane, 20:80) to give 0.014 g (0.058 
mmol) of 23 in 30% yield as yellow oil. 1H NMR (500 MHz, Chloroform-d) δ 8.02 – 7.92 
(m, 1H), 7.82 – 7.75 (m, 1H), 7.50 (dddd, J = 27.5, 8.2, 6.8, 1.4 Hz, 2H), 5.42 (t, J = 2.8 
Hz, 1H), 3.87 (dq, J = 9.7, 7.1 Hz, 1H), 3.71 (dq, J = 9.7, 7.1 Hz, 1H), 3.19 – 3.01 (m, 2H), 
2.64 (s, 3H), 2.25 (ddt, J = 13.2, 6.5, 3.3 Hz, 1H), 2.17 – 1.98 (m, 1H), 1.18 (dt, J = 15.6, 
7.0 Hz, 3H). 
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3,3,5-trimethyl-1H-[1,3]dioxino[4,5-c]quinoline (29): Quinoline diol 10a (110 mg, 0.59 
mmol, 1 eq) was combined with p-TsOH•H2O (10 mg, 0.053 mmol, 0.11 eq), 2,2-
dimethoxypropane (2.5 mL, 20 mmol, 30 eq), and anhydrous MgSO4 (90 mg, 0.75 mmol, 
1.3 eq) in 10 mL acetone and stirred at 50 °C for 5 days. Reaction was concentrated and 
the residue was dissolved in EtOAc (50 mL) and water (50 mL), extracted with EtOAc (2 
x 30 mL) washed with 1 M NaOH aq. (2 x 25 mL), dried over MgSO4,and concentrated. 
Purified by flash column chromatography (EtOAc:Hexane, 5:95) to give 110 mg (0.50 
mmol) of 29 in 84% yield as a white solid. 1H NMR (300 MHz, Chloroform-d) δ 7.97 (dt, 
J = 8.2, 1.0 Hz, 1H), 7.60 – 7.43 (m, 3H), 5.17 (s, 2H), 2.61 (s, 3H), 1.62 (s, 6H). 13C NMR 
(101 MHz, CDCl3) δ 152.08, 143.61, 141.82, 129.21, 126.58, 126.23, 124.06, 120.55, 
118.11, 100.03, 58.80, 24.57, 19.84. 
 
 
3,3,5,6-tetramethyl-1H-[1,3]dioxino[4,5-c]quinolin-6-ium (30): Solid quinoline ketal 29 
(93 mg, 0.41 mmol, 1 eq) was dissolved in methyl iodide (5 mL) in a Schlenk flask. Flask 
was sealed and stirred at 50 °C for 3 days. Yellow powder was isolated and washed with 
hexane to give 120 mg (0.34 mmol) of 30 in 81% yield. 1H NMR (300 MHz, DMSO-d6) δ 
8.53 (d, J = 8.9 Hz, 1H), 8.14 – 7.99 (m, 2H), 7.99 – 7.88 (m, 1H), 5.54 (s, 2H), 4.46 (s, 
3H), 2.89 (s, 3H), 1.63 (s, 6H). 13C NMR (101 MHz, DMSO) δ 154.07, 143.65, 133.93, 
131.75, 129.77, 129.27, 124.00, 123.82, 119.36, 102.29, 58.67, 24.17, 15.33. 
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3-hydroxy-4-(hydroxymethyl)-1,2-dimethylquinolin-1-ium (28): Quinolinium ketal 30 
(52 mg, 0.14 mmols, 1 eq) was dissolved in water (1 mL) and acetic acid (4 mL) and 
refluxed for 6 hours. Reaction was concentrated and purified by HPLC (Water:Acetonitrile, 
95:5) to give 29 mg (0.087 mmol) of 28 in 62% yield as a white solid. 1H NMR (500 MHz, 
Methanol-d4) δ 8.42 (dt, J = 9.0, 0.8 Hz, 1H), 8.22 (ddd, J = 8.6, 1.5, 0.9 Hz, 1H), 7.97 
(ddd, J = 9.0, 7.0, 1.3 Hz, 1H), 7.90 – 7.83 (m, 1H), 5.55 (s, 1H), 4.53 (s, 2H), 3.02 (s, 3H). 
  
 
3-(hydroxymethyl)naphthalen-2-ol (4):42 3-hydroxy-2-napthoic acid (0.98 g, 5.3 mmol, 
1 eq) dissolved in THF (10 mL) was added dropwise to a solution of sodium borohydride 
(0.240 g, 6.4 mmol, 1.2 eq) dissolved in THF (10 mL). The reaction was cooled to 0 °C 
and iodine (0.67 g, 2.7 mmol, 0.5 eq) dissolved in THF (10 mL) was added dropwise. The 
reaction was stirred at room temperature overnight, quenched with 3 M HCl (4 mL), diluted 
with water (20 mL) and extracted with ethyl ether (3 x 10 mL). The combined organic 
layers  were extracted with 3 M NaOH (3 x 10 mL), neutralized with 3 M HCl, and the 
white precipitate was isolated with suction filtration and washed with water (15 mL) to 
yield 0.20 g (1.15 mmol) of 3 in 22% yield as a white solid.1H NMR (300 MHz, DMSO-
d6) δ 9.82 (s, 1H), 7.80 (s, 1H), 7.76 (d, J = 8.0 Hz, 1H), 7.64 (d, J = 8.2 Hz, 1H), 7.37 – 
7.28 (m, 1H), 7.28 – 7.20 (m, 1H), 7.09 (s, 1H), 5.16 (t, J = 5.6 Hz, 1H), 4.62 (d, J = 5.6 
Hz, 2H). 
 
 
2-((dimethylamino)methyl)quinolin-3-ol (13c): dimethylmethylideneammonium iodide 
(410 mg, 2.2 mmol, 1.5 eq) and K2CO3 (100 mg, 0.71 mmol, 0.5 eq) were added to a 
solution of 3-hydroxyquinoline (18) (210 mg, 1.4 mmol, 1 eq) dissolved in DCM (10 mL). 
N
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The reaction was refluxed for 16 hours. After cooling to room temperature, the solid was 
isolated with vacuum filtration. The solid was dissolved in MeOH (50 mL) and the filtrate 
was isolated and concentrated to yield 280 mg (2.2 mmol) of 13c in > 95% crude yield as 
a yellow solid, which was used without further purification. 1H NMR (500 MHz, DMSO-
d6) δ 8.73 (s, 1H), 8.19 – 8.13 (m, 1H), 8.01 – 7.95 (m, 1H), 7.68 – 7.56 (m, 3H), 4.59 (s, 
2H), 2.74 (s, 6H). 13C NMR (126 MHz, DMSO-d6) δ 150.50, 143.12, 142.55, 129.66, 
127.79, 127.67, 126.29, 123.01, 115.26, 49.77, 43.00. 
 
 
2-((dimethylamino)methyl)-3-hydroxy-1-methylquinolin-1-ium (31): Dimethyl sulfate 
(12.5 mL, 132 mmol, 100 eq) was added to a solution of quinoline 13c (270 mg, 1.32 
mmol, 1 eq) dissolved in acetonitrile (100 mL). Reaction was stirred overnight at room 
temperature, quenched with water (15 mL), concentrated, and resuspended in a minimal 
amount of acetonitrile and Et2O was added slowly until a yellow precipitate formed. 
Solid was collected and washed with Et2O (3 x 10 mL) to yield 72 mg (0.24 mmol) of 31 
in 18% crude yield as a yellow solid, which was used without further purification. 1H 
NMR (500 MHz, Methanol-d4) δ 9.08 (s, 1H), 8.58 – 8.52 (m, 1H), 8.49 (d, J = 8.9 Hz, 
1H), 8.15 – 8.05 (m, 2H), 5.06 (s, 2H), 4.74 (s, 3H), 3.67 (s, 3H, H3COSO3-), 3.04 (s, 
6H). 
 
 
2-aminobenzaldehyde (15): Iron powder (5.54g, 99.2 mmol, 10 eq) and concentrated HCl 
(0.1 ml) were added to a solution of 2-nitrobenzaldehyde (14) (1.54 g, 10.2 mmol, 1 eq) in 
37.5 ml ethanol/water (4:1). The reaction was heated to reflux for 2 h., cooled to room 
temperature, diluted with 100 ml EtOAc, dried over anhydrous MgSO4, and filtered. The 
filtrate was concentrated and purified by column chromatography on silica 
(EtOAc:Hexane, 10:90) to give 740 mg (6.1 mmol) of 2-aminobenzaldehyde (15) in 61% 
yield as a yellow solid: 1H NMR (500 MHz, Chloroform-d) δ 9.87 (s, 1H), 7.52 – 7.45 (m, 
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1H), 7.35 – 7.26 (m, 1H), 6.79 – 6.70 (m, 1H), 6.68 – 6.62 (m, 1H), 6.11 (s, 2H); 13C NMR 
(126 MHz, Chloroform-d) δ 194.24, 150.00, 135.87, 135.34, 118.99, 116.54, 116.15, 
77.41, 77.16, 76.91. 
 
 
ethyl 3-aminoquinoline-2-carboxylate (16): Ethyl bromopyruvate (0.8 mL, 6.6 mmol, 
1.05 eq) dissolved in EtOH (11 mL) was added dropwise to a solution of pyridine (0.5 mL, 
6.4 mmol, 1.05 eq) dissolved in EtOH (16 mL). The reaction was heated to 60 °C for 1.5 
hr and then cooled to room temperature before 15 in EtOH (2 mL) and pyridine (1.2 mL) 
were added. The reaction was heated to 90 °C for 5 hr and then cooled to room temperature 
before pyrrolidine (1.2 mL, 14.6 mmol, 2.4 eq) was added and the reaction was heated to 
70 °C for 2 hr. Reaction was purified with flash column chromatography (EtOAc:Hexane, 
30:70) to give 760 mg (3.5 mmol) of quinoline 16 in 58% yield as yellow solid. 1H NMR 
(500 MHz, Chloroform-d) δ 8.08 – 8.02 (m, 1H), 7.60 – 7.54 (m, 1H), 7.49 – 7.41 (m, 2H), 
7.26 (s, 1H), 4.55 (q, J = 7.1 Hz, 2H), 1.52 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, 
Chloroform-d) δ 167.25, 142.86, 141.59, 134.35, 131.40, 130.61, 129.08, 126.16, 125.31, 
118.79, 77.48, 77.16, 76.84, 62.24, 14.51. 
 
 
ethyl 3-hydroxyquinoline-2-carboxylate (17): Aminoquinoline 16 (480 mg, 2.2 mmol, 1 
eq) was dissolved in 40% sulfuric acid solution (3 mL) at room temperature. To this was 
added ice (3 g) and the mixture was stirred for 5 min to form an orange paste and then 
cooled to 0 °C. NaNO2 (190 mg, 2.4 mmol, 1.1 eq) in water (1 mL) was added dropwise 
to the reaction. the reaction was stirred for 15 min at 0 °C before being transferred to a 
refluxing solution of 50% sulfuric acid (20 mL). The reaction was refluxed for 10 min 
before being poured over ice water (100 mL). Reaction was neutralized with NaHCO3, 
extracted with EtOAc (3 x 150 mL), washed with brine (50 mL), dried over MgSO4, and 
concentrated. Reaction was purified with flash column chromatography (EtOAc:Hexane, 
N
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12:88) to give 153 mg (0.7 mmol) of quinoline 17 in 32% yield as yellow solid. 1H NMR 
(500 MHz, Chloroform-d) δ 10.51 (s, 1H), 8.12 (dd, J = 8.5, 1.7 Hz, 1H), 7.72 – 7.66 (m, 
2H), 7.58 – 7.51 (m, 2H), 4.61 (q, J = 7.1 Hz, 2H), 1.53 (t, J = 7.1 Hz, 4H). 13C NMR (101 
MHz, Chloroform-d) δ 169.73, 154.39, 143.04, 133.05, 132.50, 130.99, 129.85, 127.99, 
126.73, 121.17, 77.79, 77.48, 77.16, 63.60, 14.73. 
 
 
2-(hydroxymethyl)quinolin-3-ol (13a): A solution of quinoline ester 17 (230 mg, 1.1 
mmol, 1 eq) in THF (20 mL) was added dropwise to DIBAL 1 M in THF (5.3 mL, 5.3 
mmol, 5 eq) at 0 °C and stirred at room temperature for 4.5 hr. Reaction was quenched by 
the slow dropwise addition of saturated Rochelle salt aq (20 mL) at 0 °C. The solution was 
stirred overnight at room temperature, extracted with EtOAc (3 x 25 mL), washed with 
brine (1 x 25 mL), dried over MgSO4, and concentrated. Reaction was purified with flash 
column chromatography (Methanol:DCM, 5:95) to give 170 mg (0.96 mmol) of quinoline 
13a in 91% yield as white solid. 1H NMR (500 MHz, DMSO-d6) δ 10.41 (s, 1H), 7.89 (dt, 
J = 8.6, 1.0 Hz, 1H), 7.78 (dd, J = 8.0, 1.6 Hz, 1H), 7.53 – 7.41 (m, 3H), 5.03 (s, 1H), 4.72 
(s, 2H). 13C NMR (126 MHz, DMSO-d6) δ 153.29, 149.12, 141.53, 129.17, 128.37, 126.58, 
126.49, 126.25, 115.38, 61.08. 
 
 
2-(ethoxymethyl)quinolin-3-ol (13b): Quinoline 13a (55 mg, 0.27 mmol, 1 eq) was 
dissolved in absolute EtOH (10 mL) and heated to reflux for 3 days. Reaction was cooled 
to room temperature, concentrated, and purified by column chromatography on silica 
(Methanol:DCM, 1:99) to give 31 mg (0.15 mmol) of quinoline 13b in 55% yield as a 
white solid. 1H NMR (500 MHz, Methanol-d4) δ 8.56 (s, 1H), 8.13 – 8.07 (m, 1H), 7.96 – 
7.90 (m, 1H), 7.60 – 7.53 (m, 2H), 5.04 (s, 2H), 3.65 (q, J = 7.1 Hz, 2H), 2.70 (s, 1H), 
1.22 (t, J = 7.0 Hz, 3H). 
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2-(methoxymethyl)quinolin-3-ol (26): Quinoline diol 13a (59 mg, 0.34 mmol, 1 eq) in 
H2O:MeOH (1:1, 200 mL) was irradiated with a 300 W Hg arc lamp (Oriel Instruments) 
using a 320 nm long pass filter and UG-II filter for 6 hours in a 300 mL Quartz RBF. 
Methanol was removed under reduced pressure and the photolysis product was extracted 
with EtOAc (3 x 25 mL), dried over MgSO4, and concentrated. Purified by flash column 
chromatography (EtOAc:Hexane, 20:80) to give 15 mg (0.079 mmol) of 26 in 23% yield 
as white powder. 1H NMR (500 MHz, Chloroform-d) δ 8.46 (s, 1H), 8.04 (dd, J = 8.2, 
1.2 Hz, 1H), 7.77 (dd, J = 8.2, 1.5 Hz, 1H), 7.64 – 7.57 (m, 2H), 7.54 (ddd, J = 8.1, 6.8, 
1.3 Hz, 1H), 5.11 (s, 2H), 3.66 (s, 3H). 13C NMR (126 MHz, Chloroform-d) δ 150.32, 
147.49, 142.60, 129.45, 128.67, 127.01, 126.95, 126.50, 118.49, 76.84, 59.32. 
 
 
2-ethoxy-3,4-dihydro-2H-pyrano[3,2-b]quinoline (27): Quinoline 13a (48 mg, 0.23 
mmol, 1 eq) and ethyl vinyl ether (1 ml, 10 mmol, 50 eq) in H2O:MeCN (1:1, 200 mL) was 
irradiated with a 300 W Hg arc lamp (Oriel Instruments) using a 320 nm long pass filter 
and UG-II filter for 5 hours in a 300 mL quartz RBF. Acetonitrile was removed under 
reduced pressure and product was extracted with EtOAc (3 x 25 mL) dried over MgSO4 
and concentrated. Purified by flash column chromatography (EtOAc:Hexane, 15:85 to 
20:80) to give 15 mg (0.066 mmol) of 27 in 28% yield as clear oil. 1H NMR (500 MHz, 
Chloroform-d) δ 7.96 (dq, J = 8.5, 0.9 Hz, 1H), 7.67 (ddd, J = 8.2, 1.5, 0.7 Hz, 1H), 7.53 
(ddd, J = 8.4, 6.9, 1.5 Hz, 1H), 7.48 (s, 1H), 7.42 (ddd, J = 8.1, 6.8, 1.2 Hz, 1H), 5.35 (t, J 
= 2.7 Hz, 1H), 3.89 (dq, J = 9.6, 7.1 Hz, 1H), 3.68 (dq, J = 9.6, 7.1 Hz, 1H), 3.38 (ddd, J = 
17.2, 12.5, 6.3 Hz, 1H), 3.07 (ddd, J = 17.2, 6.0, 3.2 Hz, 1H), 2.28 (ddt, J = 13.6, 6.2, 3.0 
Hz, 1H), 2.18 (dddd, J = 13.5, 12.4, 6.0, 2.6 Hz, 1H), 1.18 (t, J = 7.1 Hz, 3H). 13C NMR 
(126 MHz, Chloroform-d) δ 148.87, 146.95, 143.52, 128.88, 128.40, 127.09, 126.50, 
126.17, 119.24, 97.12, 64.05, 26.84, 25.09, 15.19. 
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4.6.3   Quantum Yield of Fluorescence 
Sample preparation and data collection. All UV-vis and fluorescence 
experiments were performed using EMD Millipore (OmniSolveÒ) grade solvents in 1 cm 
pathlength quartz cuvettes open to air. All UV-Vis absorbance measurements were on a 
Cary 60 spectrometer. Emission spectra were recorded on a Jobi Yvon Spec Fluorolog-3-
11. Samples were excited with a Xe arc lamp with a monochromator providing wavelength 
selection. Right angle emission was filtered using a monochromator and detected with a 
Hamamatsu R928P photomultiplier tube with photon counting. All emission and excitation 
spectra were subtracted from blank spectra recorded at the same wavelength on the same 
day.  
Quantum yield of fluorescence measurements were determined by comparison to 
the established standard quinine sulfate in 0.5 M sulfuric acid.43,44 Five samples of each 
compound to be tested, in 0.1 M phosphate buffer, and the standard were prepared with 
absorbance at 325 nm between 0.015 and 0.1 to minimize the effect of self-quenching and 
nonlinear effects. Emission spectra, with excitation at 325 nm, were collected for all 
samples and the maximum fluorescence intensity was recorded.  
Analysis. The quantum yield of fluorescence F for the compound (x) is related to 
the known quantum yield of fluoresce for a standard (st) by the formula: !" = !$% &'()*&'()+, -*.-+,. 	 	 	                 (4. 1) 
where Grad is the gradient generated from plotting the fluorescence intensity against 
absorbance and h refers to the refractive index of the respective solvent. The refractive 
index of 0.1 M phosphate buffer and 0.5 M sulfuric acid were assumed to be the same.45  
  
4.6.4   Transient Absorption Spectroscopy  
Samples were dissolved in water or trifluoroethanol (TFE) and the concentration 
was diluted to an A350 < 0.3 and placed in a four-sided quartz cuvette with a small stir bar 
and sealed with a Teflon cap. For quenching experiments stock solution of NaN3 (1 M and 
10 mM) and MeOH (1 M), were serial diluted to the desired concentration. For EVE 3 µL 
was added to 3 mL solution of quinoline dissolved water of TFE.  
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Single wavelength transient absorption measurements were performed at the 
Beckman Institute Laser Resource Center (California Institute of Technology). Samples 
were excited using a 355 nm laser pulse, 8 ns, at 10 Hz provided by the third harmonic 
from a Q-switched Nd:YAG laser (Spectra-Physics Quanta-Ray Pro-Series). Probe light 
provided by a 75-W Xe arc lamp (PTI Model A 1010) was passed through the sample 
collinearly and was operated in continuous wave or pulsed modes depending timescale of 
observation. Short-pass and long-pass filters were used to remove scattered excitation light 
and a neutral density filter was used to regulate light intensity before the probe wavelength 
was selected by a double monochromator (Instruments SA DH-10) with a 1 mm slit. Light 
was detected with a photomultiplier tube (PMT, Hamamatsu R928) and amplified using a 
200 MHz wideband voltage amplifier (FEMTO, DHPVA-200). All instruments and 
electronics were controlled by software written in LabView (National Instruments). Data 
were recorded in units of DOD. (DOD = -log10(I/I0),  where I is the time resolved probe 
light intensity with laser excitation, and I0 is the intensity without excitation.) At each 
wavelength of observation around 100 shots were averaged, the data were log-compressed 
and then fit in MATLAB (Mathworks, Inc.).46  
 
4.6.5   pH Dependent Relative Quantum Yield of Reaction 
 Sample Preparation for Photolysis: Stock solutions of citrate-phosphate buffer, 
pH 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, and 6.0, were prepared as described previously.43 Buffer, 0.5 
mL, was added to a solution of quinoline 10a or 13a in absolute ethanol (0.5 mL, 0.001 M) 
in a custom 10 mL quartz test tube. The mixture was shaken thoroughly and 0.35 mL were 
transferred to an amber HPLC vial and capped as a dark control. The remaining 0.65 mL 
was sealed for photolysis experiments.  
 Photolysis: The prepared samples were irradiated using a 150 W Hg arc lamp 
(Oriel Instruments) with a UG-II filter on a custom-made merry-go-round apparatus 
rotating at 20 rpm mounted on an optical rail to minimize variation in light exposure. Upon 
completion the test tubes were uncapped and the solution was transferred to an amber 
HPLC vial and capped for analysis. Paired samples (dark and irradiated) were randomized 
before running on an Agilent 1100 LCMS equipped with a diode array detector.  
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 Data collection and analysis: Quantitative analysis for the photolysis of 10a and 
13a was performed by on a LCMS using a 5% to 95% acetonitrile in water gradient and 
integrating the peak corresponding to the ether product 10b or 13b in the 254 nm 
absorbance trace. Dark control samples were subtracted to control for thermal QM reaction. 
Samples were normalized to a concurrently run pH 6 sample. All experiments were run in 
triplicate and plotted using prism (GraphPad).  
 
4.6.6   Quantum Yield of Reaction 
General: All chemicals and solvents were purchased at the highest grade available 
(Spectral grade). Samples were prepared in custom 10 mL quartz test tubes, sealed with a 
Teflon cap. Samples were photolyzed using a 300 W Hg arc lamp (Oriel Instruments) with 
a 320 nm long pass filter and UG-II filter on a custom-made merry-go-round apparatus 
rotating at 20 rpm. All procedures were carried out in darkness with a dim red filtered 
safety light. Data were collected on an Agilent 1260 HPLC equipped with a diode array 
detector. Absorbance spectra were recorded on a Cary 60 using 10 mm quartz cuvettes.     
Synthesis of potassium ferrioxalate: In the dark 1.5 M potassium oxalate 
monohydrate (300 mL) was mixed with 1.5 M ferric chloride hexahydrate (100 mL) and 
stirred in the dark for 30 min at room temperate. The solid was collected, recrystallized 
three times from warm water, and dried over warm air overnight to produce lime green 
potassium ferrioxalate trihydrate crystals, which were allocated into 60 mg amounts and 
stored in the dark at room temperature.  
Ferrioxalate actimometry: Immediately before use and in the dark, potassium 
ferrioxalate (60 mg) was dissolved in 0.05 M H2SO4 (20 mL) and shaken to ensure a 
homogeneous solution. In addition, a solution of 1,10-phenanthroline (40 mg) in 1 M 
sodium acetate buffer (20 mL; made by adding 82 g of NaOAc•3H2O and 10 mL H2SO4 
to 1 L of H2O) was prepared.  
Using a 1 ml gas-tight syringe fitted with a four inch needle, 0.5 mL of potassium 
ferrioxalate solution was transferred to a quartz test tube, capped and irradiated. Upon 
completion, 0.1 mL was transferred to a vial containing 0.8 mL of the 1,10-phenanthroline 
solution and 1.1 mL of water measured using a volumetric pipet.  The solution was 
developed in the dark for 45 min before being transferred to a cuvette and UV-Vis 
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absorbance spectrum taken. The average absorbance of three samples irradiated for five 
minutes was used to determine a photon flux per minute for the lamp.  
 Sample Preparation for Photolysis: A solution of 10a (0.95 mL) in 0.01 M 
phosphate buffer/acetonitrile (1:1) with an absorbance between 0.05 and 0.1 at 330 nm was 
transferred to an amber HPLC vial and 0.05 ml of ethyl vinyl ether. The mixture was shaken 
thoroughly and 0.5 mL was transferred to a quartz test tube, sealed, and irradiated. The 
remaining 0.5 mL was capped for HPLC analysis and stored in the dark.   
 Photolysis: The prepared samples were irradiated using a Hg arc lamp and a merry-
go-round apparatus mounted on an optical rail to minimize variation in light exposure. 
Upon completion the test tubes were uncapped and the solution was transferred to an amber 
HPLC vial and capped for analysis. Paired samples (dark and irradiated) were randomized 
before running on HPLC.  
 Data collection: In general, quantitative analysis for the photolysis of 10a was 
performed by HPLC using an isocratic elution of 5% acetonitrile in water and integrating 
the peak corresponding to 23 in the 254 nm absorbance trace. Quantitative analysis for the 
photolysis of potassium ferrioxalate was performed by UV/Vis spectroscopy, and 
measuring the absorbance at 510 nm corresponding to the Fe2+ -phenathroline complex.  
Calculations of the quantum yield: The quantum yield for the disappearance of 
10a (Fs) due to photolysis is given by equation 4.2,  !$ = /+0+     (4. 2) 
where ns is the number of moles of the sample consumed, and ps is the number of moles of 
photons absorbed by the sample. The amount of the sample consumed can be represented 
by the difference in the number of mole pre- and post-photolysis (Equation 4.3), which can 
be calculated from integrations of HPLC traces (Is) with the use of a calibration function 
(f), and the volume of the photolysis sample (V).  1$ = 2 3$)('4 − 3$67 8    (4. 3) 
The moles of photons absorbed ps is measured using the ferrioxalate actinometer 
(Equation 4.4) where C is an absorbance correction factor typically measured as the 
transmittance of the sample divided by the transmittance of the potassium ferrioxalate 
(Fe3+) solution before irradiation at the wave length of irradiation. However, given that the 
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sample was irradiated over a range of wavelengths the transmittance between 330 and 365 
nm was integrated for both the potassium ferrioxalate (Fe3+) solution and the sample 
(Equation 4.5) The range of 330 to 365 nm was determined by region the UG II and 320 
nm long pass filters allowed at least 50% transmittance. 9:(;0<= = > ∙ /@A.BC@A.B	     (4. 4) > = E+FGHFFI 	∙EJ	K,	FFI	E@AFBFGHFFI 	∙E@A.B	K,	FFI        (4. 5) 
fFe2+ is the known quantum yield for Fe2+ generation (1.23 at 350 nm) and nFe2+ the moles 
of Fe2+ produced. The latter can be determined by the absorbance of the Fe2+-
phenanthroline complex at 510 nm (AbsFe2+), the known extinction coefficient e of the 
complex (11100 M-1cm-1) and the photolysis volume as given in equation 4.6: 1L=MN = OP$@A.∙QR∙QFS∙Q.      (4. 6) 
where V1is the total irradiation volume, V2 is the volume developed, and V3 is the volume 
of developed solution.  
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Chapter 5 
 
ATTEMPTS AT IMPROVING THE EFFICIENCY OF QUINONE 
TRIMETHYL LOCK PROTECTINE GROUP USING A RADICAL 
DECARBOXYLATION STRATEGY  
 
Abstract 
The quinone trimethyl lock system has proved to be an efficient 
photoremovable protecting group for amine and alcohols. Efforts to extend 
the quinone chromophore to longer wavelengths and to improve the 
efficiency of the photochemical reduction have proved challenging. A 
radical decarboxylation strategy was tested to improve quantum efficiency 
and increase reactivity at longer wavelengths by trapping the charge transfer 
state. A glycine was installed on both a benzoquinone and a phenoxazine 
substrate and the photochemistry of both was evaluated.  Both derivatives 
proved stable to irradiation.  
 
5.1   Introduction 
Our lab recently published a series of visible light triggered photoremovable 
protecting groups for alcohols and amines based on a quinone trimethyl lock (TML)1,2 
(Figure 5.1) and more recently based on a quinone cis-alkenyl lock.3 The TML is a highly 
versatile decaging system; the unmasking of a phenol results in rapid cyclization of either 
an ester or amide and the releases of an alcohol or amine respectively in seconds to minutes. 
The increased rate of lactonization is due to the three interlocking methyl groups 
prepositioning the substrate into a conformer similar to the transition state and the relief of 
strain achieved upon cyclization.4,5 Previously, unmasking of a phenol for TML chemistry 
has been achieved using chemical or enzymatic means to remove a protecting group or 
reduction of a quinone to a hydroquinone. This was the first time TML release was 
achieved by photoreducing a quinone with visible light.  
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Figure 5.1: Visible light triggered photoremovable quinone trimethyl lock (TML) protecting group. 
 
Amine substituted quinones and naphthoquinones are known to be photoreactive: 
on exposure to visible light, 2,5-diamino-1,4-benzoquinone (1), undergoes a formal 
hydrogen shift from the amine substituent to the quinone core, oxidizing the amine and 
reducing the quinone. The final product in most cases is a cyclized benzoxazoline 2 (Figure 
5.2a).6–17 A correctly positioned alky substitutes is required: primary amine substituted 
quinones are photostable because hydrogen bonding orients the alkyl substituent away 
from the quinone carbony13 and aziridno and azetidino amine substituents are inert to 
photolysis because of a too long O---H distance (Figure 5.2b).12  
	  
Figure 5.2: Aminoquinone and aminonaphthoquinone photochemistry. a) Photoreduction of amine 
substituted quinones and naphthoquinones primarily result in cyclized benzoxazoline products. b) 
photostability of aziridino and azetidino and primary amines.  
 
Addition of an electron donating amine to the quinone results in a broad visible 
light charge transfer band. Excitation of this long wavelength band results in considerable 
charge transfer from the amine to the quinone carbonyl oxygen. It is understood that it is 
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this polar state that undergoes a proton transfer in the primary photochemical step of the 
mechanism. With increasing solvent polarity, the quantum yield of reaction decreases most 
likely due to influences of the dielectric constant and hydrogen bonding on the charge 
transfer excited state.9,17 Detailed mechanistic studies on dialkylamino-1,4-napthoquinones 
showed no radical species after photolysis at 77 K but did identify two intermediates that 
when warmed formed the photolysis product.8,9 Work in our lab by Regan et al. showed 
that for sulfide substituted TML quinone 5 reaction occurred from both the singlet and 
triplet charge transfer state supporting a sequential ionic mechanism (Scheme 5.1).2  
	   
Scheme 5.1: Mechanism for the photoreduction of alkyl sulifide substituted quinones.  
 
Alternatively, direct conjugation of the amine and quinone allows for hydrogen 
atom transfer (HAT) to an n,p* carbonyl in a standard radical mechanism through a 
conventional Norrish II reaction. However, Norrish type II reactions experience opposite 
solvation effects; increasing solvent polarity increases the quantum yield of the reaction.18 
Additionally, when radical clocks 5-hexenyl, cyclopropylmethyl and 2-
phenylcyclopropylmethyl where included in sulfide substituted TML quinone derivatives 
no discernable radical products were detected.2 Compared to the HAT mechanism, the 
proposed mechanism of sequential electron transfer followed by proton transfer should be 
energetically favorable at longer wavelengths. 
Efforts in our lab to extend the wavelength of reaction for quinone derivatives have 
suffered from lower quantum yields of reaction and in some cases, did not react at all. 
Regan et al. showed that for sulfide substituted quinones the majority of molecules excited 
to the charge transfer state, between 92-98%, relaxed nonradiatively back to the ground 
state without undergoing proton transfer.2 It was hypothesized that if the quinone could be 
trapped in the charge transfer state with radical decarboxylation, then the quantum yield of 
the reaction could be improved.  
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In the presence of either an inter- or intramolecular electron donor, carboxylic acids 
and their respective anions can be photochemically decarboxylated resulting in a carbon 
radical.19 Photochemical radical decarboxylation has been used in organic synthesis,20–22 
and for protecting groups.23,24 It was envisioned that a quinone with a correctly positioned 
glycine carboxylic acid derivative could be photoreduced (Scheme 5.2). Upon excitation 
electron transfer from the amine to the quinone would result in charge transfer state 10 
which could undergo radical decarboxylation trapping the charge transfer state 11. The 
radical decarboxylation of glycine derivatives is fast, on the order of 100 ns25 and could 
provide a generalizable alternative to proton abstraction for quinone photoreduction. 
Subsequent electron transfer and proton transfer from bulk solvent would result in imine 
hydroquinone 12 which could react with water to form hydroquinone 13 or cyclize to form 
hydroquinone 14. This would be the first example of an intramolecular radical 
decarboxylation quinone photocage. Two quinones were synthesized and their 
photochemistry explored in this chapter.  
 
Scheme 5.2: Proposed quinone radical decarboxylation photoreduction.   
 
5.2   Results 
5.2.1   Synthesis of Phenoxazine 15 
Since the photoreduction of the quinone and the trimethyl lock reaction are distinct 
events,  quinone derivatives lacking the TML moiety can be screened for photoreactivity 
greatly simplifying the synthesis. Initial designs for a radical decarboxylation assisted 
quinone photoreduction focused on the red shifted phenoxazine quinone derivative 15 
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(Scheme 5.3).26 Dichloro-naphthoquinone 16 was reacted with the phenol 17 to yield the 
dark blue solid phenoxazine quinone 18.26 Attempts at direct oxidation of alcohol 18 to the 
carboxylic acid 15 proved impossible as the quinone was not stable under all standard 
oxidation conditions tested. Instead a two-step oxidation strategy was employed. Reaction 
of phenoxazine quinone 18 with Dess-Martin periodinane (DMP) afforded aldehyde 19 in 
good yield, and subsequent oxidation with buffered NaClO2 in the presence of radical 
scavenger 2-methyl-2-butene resulted in the desired carboxylic acid 15.27  
 
Scheme 5.3: Synthesis of phenoxazine 15 
 
5.2.2   Phenoxazine Photochemistry 
UV-vis of phenoxazine 15 showed a broad charge transfer band centered around 665 
nm in aqueous buffer. 15 was stable to irradiation at > 600 nm in pH 7 buffered water 
(Figure 5.3a,b). The reaction was monitored by UV-Vis and LCMS, and no appearance of 
photoproduct or disappearance of starting material was observed. Freeze pump thawing to 
remove oxygen had no effect nor did changing solvent to acetonitrile or acetonitrile/buffer 
50:50. Irradiation at shorter wavelengths ( > 335 nM) did not result in any appreciable 
photochemistry. Addition of EDTA, a sacrificial reductant, had no effect. It should be noted 
that samples were only irradiated for a total of 30 minutes. At the time, all quinone 
derivatives tested in our lab showed significant photo bleaching in a couple of minutes. 
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However, since then members of the lab have characterized quinones that exhibit slower 
photobleaching.28 Longer irradiation periods may reveal phenoxazine 15 does undergo 
radical decarboxylation and photoreduction of the quinone but this is unlikely. Concurrent 
work by David Walton in the lab showed that other cyclic quinones did not undergo the 
desired photochemistry28 (Figure 5.3c) and it was proposed that a twisted charged transfer 
state29,30 was required for the desired photochemistry to occur. Phenoxazine 15 is cyclic 
and cannot twist in the excited state, and therefore the photostability of 15 does not 
conclusively eliminate radical decarboxylation as a strategy for improving photoreduction 
efficiency because under the proposed mechanism radical decarboxylation occurs from the 
charger transfer state (Scheme 5.2).  
 
Figure 5.3: Photochemistry of phenoxazine 15. A) Predicted photochemical products. B) Change in UV-Vis 
over 30 minuets when phenoxazine 15 was irradiated at > 600 nm in aqueous phosphate buffer. C) Cyclic 
thiol quinone TML 22 is photostable compared with equivalent acyclic Quinone TML 23.  
 
5.2.3   Synthesis of an acyclic quinone 
Focus then shifted towards the synthesis of a non-cyclic quinone that could adopt a 
twisted confirmation in the excited state and contained a glycine substituent for radical 
decarboxylation (Scheme 5.4). For proof of concept it was determined that far red 
absorption was not necessary and instead efforts focused on a shorter wavelength absorbing 
benzoquinone derivative.  
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Scheme 5.4: Retrosynthesis for a acyclic glycine substituted benzoquinone. 
 
Initial synthetic efforts focused on using Buchwald-Hartwig cross-coupling to 
attach the desired amine, iminodiacetic acid (IDA) to quinone 24, which had previously 
been synthesized in our lab (Scheme 5.4, Route 1). This proved challenging. Despite 
screening common Buchwald-Hartwig reaction conditions, decomposition of the quinone 
starting material was observed every time (Table 5.1).31,32 Subsequent screening using 
morpholine as the amine showed that the problem was stability of the quinone, and not the 
atypical amine used in the cross coupling.   
 
Table 5.1: Buchwald-Hartwig reaction conditions screened in an attempt to synthesize quinone 25.   
 
Entry Amine Base Solvent Temp Time (hr) Outcome 
1 R=CH2CO2H Cs2CO3 THF 80 20 Decomposed  
2 R=CH2CO2H Cs2CO3 Toluene 80 20 Decomposed 
3 R=CH2CO2H Cs2CO3 tBuOH 90 20 Decomposed 
4 R=CH2CO2H LiHMDS THF 90 6 Decomposed 
5 R=CH2CH2OH LiHMDS THF 90 20 Decomposed 
6 Morpholine Cs2CO3 tBuOH 90 40 Decomposed 
7 Morpholine LiHMDS THF 90 20 Decomposed 
 
Given the issues of appending the glycine moiety to the quinone the decision was 
made to assemble the glycine moiety and then attach it to the quinone core via a linker 
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(Scheme 5.4, Route 2). In the presence of strong base aryl amines react with alkyl halides 
to form tertiary alkylamines. Thiol aryl amines were eliminated from consideration because 
of their propensity to oxidize and form disulfides and diaminobenzenes were also 
eliminated because of the need for protecting groups. Instead we envisioned synthesis of a 
boronic acid, containing the requisite glycine functionality, which could then be coupled 
to the quinone via C-C bond formation. Remember, in the proposed photochemistry 
mechanism electron donation occurs from the glycine nitrogen; a sulfur or nitrogen linker 
is not required.  
 
Scheme 5.5: Quinone cross coupling reactions conditions. 
 
Direct coupling of boronic acids to unfunctionalized quinones and 
naphthoquinones is known in the literature.33–36 However, all literature examples had 
limited substrate scopes and none included examples of amines despite examples with 
other electron donating groups. Reaction conditions were screened using the commercially 
available boronic acid 26 as a model substrate (Scheme 5.5). No direct C-H coupling 
K2S2O8, 
Fe(SO4)•H2O
PhCl/H2O
23 °C 12 hr
(no rxn)
O
O N
B(OH)2
N
28 26
AgNO3, 
K2S2O8
DCM/H2O
23 or 80 °C 12 hr
(no rxn)
O
O N
O
O
27 28
Pd(TFA)2
Acetone
23 °C 24 hr
(no rxn)
Pd(acac)2
dppben, Cu(BF4)2
1,4-dioxane/H2O
23 °C 12 hr
(trace)
O
O N
28
O
O N
28
B(OH)2
N
O
O
Br
PdCl2(PPh3)2, Na2CO3
1,4-dioxane/H2O
80 °C 1 hr
(70% yield)
O
O N
29 26 28
 94 
conditions were found to work with boronic acid 26 and instead Suzuki-Miyaura conditions 
were identified to couple bromo quinone 29 to boronic acid 26 (Scheme 5.5). With 
coupling conditions in hand attention turned to synthesizing the desired photoreductive 
quinone 30.  
To synthesize quinone 30, 4-Bromoaniline (31) was reacted with bromoacetate 32 
in the presence of base to furnish dialkyl 33 in good yield.37,38 (Scheme 5.6) Halogen-
containing 33 was not suited to direct coupling because under Heck coupling conditions 
quinones complex with palladium and can reoxidize Pd(0) species.39 Conversion of the 
halide to the boronic acid40 proceeded smoothly with only a small amount of hydration side 
product. However, boronic acid 34 was unstable to purification and the isolated crude 
mixture was reacted directly with quinone 29 in a Suzuki coupling41 to form quinone 35. 
Finally, all that remained was hydrolysis of the diester 35 to furnish the desired quinone 
30. Quinone 35 was sensitive to both base catalyzed hydrolysis and acid catalyzed 
hydrolysis: treatment with either LiOH or formic resulted in degradation of starting 
material. Instead the very mild and selective methyl ester hydrolysis reagent trimethyltin 
hydroxide was employed.42 This resulted in the smooth generation of the diacid 30, the low 
yield was a result of problems with the work up. 
	
 
Scheme 5.6: Synthesis of acyclic quinone 30. 
Br
N
O
O
OMe
MeO
MeO
O
Br
NaI,iPr2NEt
reflux  48 hr
(98% yield)31
32
33
B(OH)2
N
O
O
OMe
MeO
B2(OH)4, KOAc
X-Phos, 
XPhos-Pd-G3
tBuOK, MeOH, 
80 °C 15 hr
34
Br
NH2
O
O
Br
N
O
O
OMe
MeO
O
O
N
O
O
OH
HO
O
O
PdCl2(PPh3)2, Na2CO3
1,4-dioxane/H2O
80 °C 2 hr
(20% yield two steps)
Me3SnOH
1,2-DCE
80 °C 12 hr
(25% yield)
29
35 30
 95 
 
5.2.4   Quinone Photochemistry 
UV-Vis spectra of acid 30 showed a broad charge transfer band centered around 475 
nm in methanol (Figure 5.4); there was a marked redshift of 35 nm in water. Acid 30 was 
stable to irradiation at 470 nm in methanol for 24 hours. The reaction was monitored by 
UV-Vis, LCMS and NMR and no appearance of photoproduct or disappearance of starting 
material was observed. Freeze pump thawing to remove oxygen had no effect on the 
photostability of 30. Acid 30 also proved photostable in water and phosphate buffer (0.01 
M, pH 7.6) when irradiated at 565 nm or 470 nm. Finally, addition of the external electron 
donor EDTA had no effect on quinone 30. Given the photostability of quinone 30 under 
all conditions tested, it was unclear if glycine based radical decarboxylation could trap the 
charge transfer state or if quinone 30 could be reduced at all. 
 
Figure 5.4: Photochemistry of quinone acid 30. A) predicted products of photochemical reductive radical 
decarboxylation of acid 30. B) UV-Vis spectra of acid 30 (orange), ester 35 (blue) and alkyl amine 28 (green) 
in methanol. C) Change in UV-Vis over 24 hours for acid 30 when irradiated at 470 nm in water after freeze 
pump thawing. 
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5.2.5   Quinone Electrochemistry 
The electrochemistry of alkyl quinone 28, ester quinone 35, and acid quinone 30, 
were investigated to determine their one electron reduction potentials. For alkyl quinone 
28 two reversible single electron reductive peaks were observed as expected for a quinone 
in acetonitrile ( -1.2 and -1.8 V respectively) (Figure 5.5a). Alkyl quinone 28 exhibited a 
large non-reversible oxidation event (0.5 V) that suppresses subsequent reduction cycling 
events. The is the result of amine oxidation and subsequent reaction of the radical amine 
cation with the electrode surface as has been observed previously for tertiary amine.43 Ester 
35 exhibited two much weaker and broader single electron reduction events than quinone 
28 (-1.1 V and -1.8 V respectively) (Figure 5.5b). It is not clear why a significant decrease 
in current is observed for both reduction events for quinone 35 compared to quinone 28 but 
this may explain the lack of reactivity for quinone 30. No similar reduction in current is 
observed for the oxidation of quinone 35, which is shifted 36 mV towards higher voltage. 
The first of the two smaller oxidation peaks is an artifact of reductive cycling and is most 
likely not the result of radical decarboxylation as it is present for both ester 35 and amine 
28 neither of which are expected to undergo decarboxylation. The second small oxidation 
peak is not an artifact of reductive cycling but it is unclear what it represents and may be 
the result of a small impurity in the sample. Acid 30 did not dissolve in acetonitrile and 
cyclic voltammetry experiments in DMF resulted in significantly broadened and weakend 
peaks for all three compounds, 30, 35, and 28, making analysis difficult.  
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Figure 5.5: Cyclic voltammetry of alkyl amine 28 (A) and ester 35 (B) performed under an inert atmosphere 
in MeCN with 0.1 M TBAPF6 at 100 mV/s. A) Quinone 28 shows two reversible reduction events. Scanning 
to positive potentials reveals one irreversible oxidation event. B) Quinone 35 shows much weaker reductive 
events relative to oxidative events when compared to quinone 28.  
 
5.3   Discussion 
It is apparent that both quinone 30 and phenoxazine 15 are photostable. No radical 
decarboxylation hydroquinone product was detected when either compound was irradiated. 
Since neither quinone 30 nor phenoxazine 15 showed any photochemical reactivity it is 
difficult to determine what is the cause of this photostability and if radical decarboxylation 
could ever work in the context of quinone photoreduction. The cyclic nature of 
phenoxazine 15 most likely explains the photostability of 15 given the theorized twisted 
nature of the charge transfer state. The photostability of quinone 30 could be the result of 
the large delocalized aromatic system of 30 which would result in a delocalized charge 
transfer state that may be less likely to undergo radical decarboxylation and subsequent 
proton transfer. Alternatively, the charge transfer state of 30 may not be long lived enough 
for radical decarboxylation to compete with other non-productive relaxation pathways. 
(The rate of glycine radical decarboxylation is on the order of 100 ns.)25 A less likely 
possibility is that the charge transfer state of reactive quinones could energetically mix or 
thermally populate the nearby n-p* state and undergo HAT. The radical decarboxylation 
quinone 30 has no extractable hydrogen making a HAT mechanism impossible. Future 
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work should focus on the direct substitution of a glycine to a quinone, as in quinone 9, to 
address concerns over the delocalized nature of an aromatic system and the possibility that 
an extractable hydrogen for HAT may be required. However, this work suggests that 
radical decarboxylation is unlikely to work as a general method for photoreducing 
quinones.  
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5.5   Experimental 
5.5.1   General Procedure  
Unless otherwise stated reactions were carried out at ambient temperatures under 
argon. Any potentially light sensitive compounds were protected from light using 
aluminum foil and carried out under low ambient light conditions. Commercially available 
reagents were obtained from Sigma Aldrich, AK scientific, Alfa Aesar, Acros Organics, or 
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Strem Chemicals. Solvents used in photolysis and UV-vis experiments were EMD 
Millipore (OmniSolveÒ) grade. Other solvents were used as received unless otherwise 
noted. Reactions were monitored with thin layer chromatography using EMD/Merck silica 
gel 60 F254 precoated class plates (0.25 mm). Flash column chromatography was 
conducted using 60 A, 230-400 mesh silica gel purchased from Alfa Aesar. NMR spectra 
were recorded on Varian (300 or 500 MHz) or Bruker (400 MHz) spectrometers. UV-vis 
spectra were obtained using a Cary 60 spectrometer. Photolysis experiments were 
conducted in a quartz cuvette using either a 300 W Hg arc lamp (66011, Oriel) with glass 
filters or a 650 mW, 470 nm LED (M4703) or a 880 mW 565 nm LED (M565L3) from 
ThorLabs.  
 
5.5.2   Synthesis   
 
 
12-(2-hydroxyethyl)-11H-benzo[b]phenoxazine-6,11(12H)-dione (18): Phenol (17) 
(110 mg, 0.65 mmol 1 eq) and Cs2CO3 (420 mg, 1.3 mmol, 2 eq) were dissolved in 
anhydrous DMF (15 mL) resulting in a dark green solution. 2,3-dichloronaphthalene-1,4-
dione (16) (150 mg, 0.68 mmol, 1.05 eq) was added and the reaction was stirred overnight 
under argon. Reaction was quenched by the addition of 200 mL of water and the dark blue 
solid was isolated with suction filtration. Purified by flash column chromatography on 
silica (EtOAc/Hexanes: 1/1) to give 170 mg (0.55 mmol) of 18 in 85% yield as a dark blue 
solid. 1H NMR (300 MHz, DMSO-d6) δ 7.96 – 7.86 (m, 2H), 7.84 – 7.74 (m, 2H), 7.05 – 
6.72 (m, 4H), 4.96 (s, 1H), 3.95 (t, J = 5.4 Hz, 2H), 3.66 (t, J = 5.4 Hz, 2H).  
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2-(6,11-dioxo-6,11-dihydro-12H-benzo[b]phenoxazin-12-yl)acetaldehyde (19): Dess 
Martin Periodinane, DMP, (112 mg, 0.26 mmol, 1.5 eq) was added to alcohol 18 (53 mg, 
0.17 mmol, 1 eq) dissolved in dry DCM (5 mL) and stirred under argon for 1.5 hours. 
Reaction was diluted with Et2O (20 mL) and an aq solution (20 mL) of sodium thiosulfate 
(100 g/L Na2S2O3) and NaHCO3 (100 g/L) was added and the reaction was vigorously 
stirred for 15 min. The organic layer was separated, washed with brine, and dried with 
MgSO4. Purified by flash column chromatography on silica (ETOAc/Hexanes: 1/3) to give 
37 mg (0.12 mmol) of aldehyde 19 in 71% yield as a dark blue solid. 1H NMR (500 MHz, 
Chloroform-d) δ 8.09 – 8.04 (m, 1H), 7.97 – 7.92 (m, 1H), 7.69 (dtd, J = 22.0, 7.4, 1.4 Hz, 
2H), 6.90 – 6.83 (m, 3H), 6.40 (dt, J = 7.2, 1.4 Hz, 1H), 4.43 (s, 2H). 
 
 
2-(6,11-dioxo-6,11-dihydro-12H-benzo[b]phenoxazin-12-yl)acetic acid (15): Aldehyde 
19 (20 mg, 0,.07 mmol, 1 eq) was added to a solution of H2O (16 mL), THF (16 mL), t-
BuOH (4 mL) and 2-methyl-1-butene (4 mL). To this was added NaH2PO4 (73 mg, 0.52 
mmol, 8 eq) and sodium chlorite (39 mg, 0.26 mmol, 4 eq) and stirred in the dark for 3 hr. 
Diluted with aq. NH4Cl (50 mL), extracted with EtOAc (3 x 50 mL). The combined organic 
layers were washed with brine (25 mL), dried over MgSO4, and concentrated. The residue 
was purified by flash chromatography (DCM/MeOH/AcOH: 99/0.5/0.5) to give 11 mg 
(0.034 mmol) of acid 15 in 53% yield as a dark blue solid. 1H NMR (500 MHz, Methanol-
d4) δ 8.01 – 7.94 (m, 2H), 7.78 – 7.68 (m, 2H), 6.89 (td, J = 7.7, 1.6 Hz, 1H), 6.84 (td, J = 
7.7, 1.4 Hz, 1H), 6.75 (dd, J = 7.8, 1.5 Hz, 1H), 6.67 (dd, J = 7.8, 1.5 Hz, 1H), 4.55 (s, 2H). 
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2-((4-bromophenyl)thio)-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione (24): Quinone 
29 (340 mg, 1.5 mmol, 1 eq) and NaOAc (140 mg, 1.65 mmol, 1 eq) were dissolved in 
MeOH (40 mL) and stirred open to air. To this was added 4-bromothiophenol (0.23 mL, 
1.65 mmol, 1.1 eq) in MeOH (10 mL) dropwise. Reaction turned bright red and was stirred 
for 20 minuets. Reaction was concentrated and the residue purified by flash column 
chromatography (ETOAc/Hexanes: 5/95) to give 463 mg (1.4 mmol) of quinone 24 in 93% 
yield as a dark red oil. 1H NMR (500 MHz, Chloroform-d) δ 7.47 – 7.39 (m, 2H), 7.25 – 
7.18 (m, 2H), 2.28 (s, 3H), 2.07 (dq, J = 24.8, 1.2 Hz, 6H). 
 
 
dimethyl 2,2'-((4-bromophenyl)azanediyl)diacetate (33): 4-Bromoaniline (31) (210 mg, 
1.16 mmol, 1 eq), methyl 2-bromoacetate (33) (1.3 mL, 13 mmol, 12 eq), NaI (360 mg, 2.1 
mmol, 1.8 eq) and i-Pr2NEt (1.2 mL, 7.0 mmol, 6 eq) were added to MeCN (20 mL). 
Reaction was refluxed for 48 hr. Diluted with water (20 mL) and DCM (20 mL), and 
extracted with DCM (3 x 20 mL). The organic layers were combined, washed with brine 
(15 mL), dried over MgSO4, and concentrated. The residue was purified with flash column 
chromatography (ETOAc/Hexanes: gradient 10/90 to 25/75) to give 420 mg (1.14 mmol) 
of bromophenyl diacetate 33 in 98 % yield as a yellow oil. 1H NMR (500 MHz, 
Chloroform-d) δ 7.33 – 7.26 (m, 2H), 6.52 – 6.44 (m, 2H), 4.12 (3, 4H), 3.76 (s, Hz, 6H). 
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dimethyl2,2'-((3',4',6'-trimethyl-2',5'-dioxo-2',5'-dihydro-[1,1'-biphenyl]-4-
yl)azanediyl)diacetate (25): A dry Schlenk flask was charged with (X-Phos) palladium(II) 
phenethylamine chloride (18 mg, 0.023 mmol, 0.01 eq), X-Phos (24 mg, 0.043 mmol, 0.02 
eq), tetrahydroxydiboron (305 mg, 3.4 mmol, 1.5 eq), KOAc (670 mg, 6.8 mmol, 3 eq) and 
KOt-Bu (4.8 mg, 0.023 mmol, 0.01 eq). The flask was sealed, evacuated and back filled 
with argon (9x).  Bromophenyl diacetate 33 (700 mg, 2.27 mmol, 1 eq) was dissolved in 
dry MeOH (10 mL) and added to the flask. The reaction was heated to 80 °C for 14.5 hours. 
The reaction was cooled to rt then filtered through a pad of celite (eluting with 150 mL 
EtOAC) and concentrated. To the crude white solid was added 1 M aq HCl (50 mL) and 
EtOAc (50 mL) and this solution was stirred for 120 min. The aq layer was extracted with 
EtOAc (3 x 30 mL) and the combined organic layers were washed with brine (30 mL) dried 
over MgSO4, concentrated to yield crude boronic acid 34. 1H NMR (500 MHz, 
Chloroform-d) δ 8.17 – 7.93 (m, 2H), 6.81 – 6.62 (m, 2H), 4.22 (s, 4H), 3.78 (s, 6H).13C 
NMR (126 MHz, Chloroform-d) δ 171.15, 150.94, 137.41, 135.00, 111.60, 53.30, 52.42. 
 
Bromotrimethylquinone 29 (260 mg, 1.1 mmol, 0.5 eq), 
Palladium(II)bis(triphenylphosphine) dichloride (21 mg, 0.03 mmol, 0.1 eq) and Na2CO3 
(260 mg, 2.3 mmol, 1 eq) were added to crude boronic acid 34 in 1,4-dioxane (20 mL) and 
H2O (6 mL). Reaction was heated open to air to 80 °C for 2 hr, and cooled to rt. Reaction 
was diluted with DCM (25 mL) and H2O (25 mL) and separated. The aq layer was extracted 
with DCM (3 x 25 mL). Combined organic layers were washed with brine and dried over 
MgSO4, concentrated, and purified with flash column chromatography (EtOAc/Hexanes: 
20/80) to give 160 mg (0.43 mmol) of quinone diester 35 in 20 % yield as a red oil. 1H 
NMR (500 MHz, Chloroform-d) δ 7.07 – 7.00 (m, 2H), 6.66 – 6.60 (m, 2H), 4.18 (s, 4H), 
3.77 (s, 6H), 2.05 (dt, J = 11.6, 1.2 Hz, 6H), 1.98 (s, 3H). 
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2,2'-((3',4',6'-trimethyl-2',5'-dioxo-2',5'-dihydro-[1,1'-biphenyl]-4-
yl)azanediyl)diacetic acid (30): Ester quinone 35 (42 mg, 0.11 mmol, 1 eq) and 
trimethyltin hydroxide (100 mg, 0.55 mmol, 5 eq) were dissolved in DCE (10 mL) and 
refluxed overnight in the dark. The reaction was cooled to rt, concentrated, and dissolved 
in EtOAc (25 mL).  Solution was washed with aq 0.01 M NaHSO4 (3 x 25 mL), Brine (25 
mL) dried over MgSO4, concentrated, and purified with flash column chromatography 
(MeOH/AcOH/DCM: 10/1/90) to give 10 mg (0.03 mmol) of quinone 30 in 25 % yield as 
a red oil. 1H NMR (400 MHz, Methanol-d4) δ 7.15 – 6.99 (m, 2H), 6.77 – 6.56 (m, 2H), 
4.21 (s, 4H), 2.07 (s, 3H), 2.05 (s, 3H), 1.96 (s, 3H).  
 
 
2-bromo-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione (29): Bromine (0.7 mL, 13.2 
mmol, 2.2 eq) dissolved in AcOH (6mL) was added dropwise to 2,3,5-
trimethylhydroquinone (1.07 g, 6.6 mmol, 1 eq) dissolved in AcOH (45 mL). Reaction was 
stirred at rt for 21 hr before diluting with H2O (500 mL). Product was extracted with EtOAc 
(3 x 200 mL). The combined organic layers were washed with brine (200 mL), dried with 
MgSO4, concentrated, and purified with flash column chromatography (EtOAc/Hexanes: 
1/99) to give 0.91 g (3.95 mmol) of bromo quinone 29 in 60 % yield as a yellow solid. 1H 
NMR (300 MHz, Chloroform-d) δ 2.23 (s, 3H), 2.13 – 2.05 (m, 6H). 
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4'-(dimethylamino)-3,4,6-trimethyl-[1,1'-biphenyl]-2,5-dione (28): 
Bromotrimethylquinone 29 (61 mg, 0.26 mmol, 1 eq), boronic acid 26 (85 mg, 0.52 mmol, 
2 eq), Na2CO3 (55 mg, 0.52 mmol, 2 eq) and palladium(II)bis(triphenylphosphine) 
dichloride (21 mg, 0.03 mmol, 0.1 eq) were added to 1,4-dioxane (4 mL) and H2O (1 mL). 
Reaction was heated to 80 °C for 1 hr, turned deep red in color, and was cooled to rt. 
Reaction was diluted with DCM (30 mL), dried over MgSO4, filtered over a pad of celite, 
and concentrated. Reaction was purified with flash column chromatography 
(EtOAc/Hexanes: 5/95) to give 49 mg (0.18 mmol) of alkyl amine quinone 28 in 70% yield 
as a purple oil. 1H NMR (500 MHz, Chloroform-d) δ 7.09 – 7.03 (m, 2H), 6.77 – 6.71 (m, 
2H), 3.00 (s, 6H), 2.07 (s, 3H), 2.05 (s, 3H), 2.02 (s, 3H). 13C NMR (126 MHz, cdcl3) δ 
188.52, 187.24, 150.39, 143.45, 140.63, 140.48, 139.65, 131.15, 120.86, 111.47, 77.41, 
77.16, 76.91, 40.40, 14.34, 12.61, 12.53.  
 
5.5.3   Cyclic Voltammetry  
Cyclic voltammetry experiments were performed using a glassy carbon working electrode, 
Ag/AgCl reference electrode, and a platinum wire counter electrode using a Bio-Logic 
potentiostat. Experiments were performed in MeCN, DMF and 0.1 M phosphate buffered 
water with 0.1 M TBAPF6 supporting electrolyte under a N2 atmosphere. Concentrations 
of compounds used were approximately 10-3 M.  Bulk electrolysis measurements were 
made using a glassy graphite plate working electrode, a platinum counter wire electrode, 
and silver wire reference electrode separated by a glass frit. Ferrocenium/ferrocene was 
used as an external reference. 
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5.5.4   Additional Data   
 
Figure 5.6: UV-Vis of phenoxazine quinone 15 in MeCN (lmax 610 nm, green), 0.01 M pH 7 phosphate 
buffer (lmax 665 nm, yellow) and a 1:1 MeCN:Buffer (lmax 660 nm, blue). 
 
Figure 5.7: UV-vis spectra of 30 in 0.01 M pH 7 phosphate buffer.  
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Figure 5.8: NMR spectra of acid 30 before and after 2 hours of irradiation at 470 nm showing no change in 
spectra.  
 
Figure 5.9: Cyclic voltammetry of alkyl amine 28 (A), ester 35 (B) and acid 30 (C) performed under an inert 
atmosphere in DMF with 0.1 M TBAPF6 at 100 mV/s.  
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